   
Omnipod  
Horizon™ Prepi[INVESTIGATOR_45860] V2. 3 Confidential  Page | 1 
 
 
Prepi[INVESTIGATOR_211498] E ffectiveness of the 
Omnipod Horizon ™ Automated Glucose Control  System  in 
Patients with Type 1 D iabetes  
 
 
IDE G190267  
Version  2.3 
November 14, 2019  
 
 
Insulet Corporation  
100 Nagog Park  
Acton , MA [ZIP_CODE] 
 
 
 
 
Confidentiality Statement:  
The information in this document contains trade secrets and commercial information that are 
privileged or confidential and may not be disclosed unless such disclosure is required by 
[CONTACT_784]. In any event, persons to whom the informati on is disclosed must 
be informed that the information is privileged or confidential and may not  be further disclosed by 
[CONTACT_476]. These restrictions on the disclosure shall apply equally to all future information supplied to 
you, which is indicated as privileg ed or confidential.  
  
   
Omnipod  
Horizon™ Prepi[INVESTIGATOR_45860] V2. 3 Confidential  Page | 2 
PROTOCOL APPROVAL  
 
 
 
Prepi[INVESTIGATOR_211499] ™ Automated Glucose Control  System in 
Patients with Type 1 Diabetes  
 
IDE G190267  
Version 2.3 
November 14, 2019  
 
 
 
____________________________________ __ 
Trang Ly MBBS FRACP PhD  - SVP, Clinical  and  
Medical Director, Insulet Corporation  
  
 
 
        _____________________  
        Date  
 
 
 
____________________________________ __ 
Bonnie Dumais, RN – Director of Clinical Affairs,  
Insulet Corporation  
  
 
 
        _____________________  
        Date  
 
 
 
____________________________________ __ 
Julie Perkins - Senior Director, Quality and Regulatory,  
Insulet Corporation  
  
 
 
        _____________________  
        Date  
  
   
Omnipod  
Horizon™ Prepi[INVESTIGATOR_45860] V2. 3 Confidential  Page | 3 
INVESTIGATOR STATEMENT  
 
Prepi[INVESTIGATOR_211499] ™ Automated Glucose Control  System in 
Patients with Type [ADDRESS_253371] (IRB) or Food and Drug Administration (FDA). Modifications 
to the study protocol are acceptable only in the form of a protocol amendment, except 
when necessary to protect the safety, rights, or welfare of subjects. I agree to await 
Institutional Review Board (IRB) and Insulet approval for the protocol, informed consent 
and documentation to be presented to subjects before initiating the study pursuant to [ADDRESS_253372] 
complaints for any of the devices utilized in this protocol, and to maintain study related 
documentation (regulatory documentation) for the perio d of time required.  I agree to 
supervise all utilization of investigational study devices and  to ensure their usage is only 
in connection with the Study . I agree to provide a Financial Disclosure Statement to 
Sponsor and will also notify Sponsor if my disclosed financial information changes 
during the Study and up to one year following the closure  of the Study. I have read and 
understand the contents of this protocol. I agree to follow and abide by [CONTACT_45906].  
I understand the information in this document contains trade secrets and commercial 
information that are pr ivileged or confidential and may not be disclosed unless such 
disclosure is required by [CONTACT_784]. In any event, persons whom the 
information is disclosed must be informed that the information is privileged or 
confidential and may not  be further disclosed by [CONTACT_476]. These restrictions on disclosure 
will apply equally to all future information supplied to me, which is indicated as 
privileged or confidential.  
_________________________________ __  
Clinical Site Investigator Name  (print)   
_________________________________ __   __________________  
Clinical Site Investigator Signature      [CONTACT_45981]™ Prepi[INVESTIGATOR_45860] V2. 3 Confidential  Page | 4 
PRINCIPAL CONTACTS  
 
Sponsor Contacts:   Trang Ly, MBBS FRACP PhD  
SVP, Clinical and Medical Director  
Insulet Corporation  
100 Nagog Park  
Acton , MA [ZIP_CODE] 
Office: [PHONE_826] 
E-mail: [EMAIL_864]  
 
  Julie Perkins  
Senior Director , Quality and Regulatory  
Insulet Corporation  
100 Nagog Park  
Acton , MA [ZIP_CODE] 
Office: [PHONE_827]  
E-mail: [EMAIL_865]   
 
Protocol Chairs :  Bruce Buckingham , MD  
    Professor, Pediatrics  
Division of Endocrinology and Diabetes  
 Stanford School of Medicine  
    [ADDRESS_253373]  
Palo Alto, CA [ZIP_CODE]  
 E-mail:  [EMAIL_866]   
 
Sue Brown, MD  
Associate Professor of Medicine  
Division of Endocrinology  
University of V irginia  
Centers for Diabetes Technology  
[ADDRESS_253374] Floor  
Charlottesville, VA  [ZIP_CODE]  
Email: [EMAIL_867]  
 
 
 
 
 
   
Omnipod  
Horizon™ Prepi[INVESTIGATOR_45860] V2. 3 Confidential  Page | 5 
TABLE OF CONTENTS  
TITLE PAGE ......................................................….......... ........................... ..................... .............. 1 
PROTOCOL APPROVAL  ................................ ................................ ................................ ...............  2 
INVESTIGATOR STATEMENT  ................................ ................................ ................................ ...... 3 
PRINCIPAL CONTACTS  ................................ ................................ ................................ ................  4 
TABLE OF CONTENTS  ................................ ................................ ................................ .................  5 
PROTOCOL SUMMARY  ................................ ................................ ................................ ................  8 
GLOSSARY OF ACRONYMS  ................................ ................................ ................................ ...... 13 
1 INTRODUCTION  ................................ ................................ ................................ .................  15 
2 OMNIPOD HORIZON™ SYSTEM STUDY DEVICE OVERVIEW  ................................ ...... 16 
2.1 Device Description of the Omnipod Horizon™ System  ................................ . 16 
3 HORIZON ™ DATA PORTAL  ................................ ................................ ...............................  [ADDRESS_253375] THERAPY - PHASE 1  ................................ ................................ .....................  33 
8.1 Visit 2  ................................ ................................ ................................ ............  34 
8.2 Visit 3  ................................ ................................ ................................ ............  35 
9 HYBRID CLOSED -LOOP - PHASE 2  ................................ ................................ ..................  36 
9.1 Target BG  Challenges  ................................ ................................ ..................  36 
9.2 Hotel/Rental House Environment  ................................ ................................ .. 37 
9.3 Visit 4  ................................ ................................ ................................ ............  37 
9.4 Visit 5  ................................ ................................ ................................ ............  38 
9.5 Visit 6  ................................ ................................ ................................ ............  39 
9.6 Visits 7, 8 and 9  ................................ ................................ ............................  39 
9.7 Visit 10 (End of Study)  ................................ ................................ ..................  39 
9.8 Unscheduled Visits  ................................ ................................ .......................  40 
9.9 Early Withdrawal  ................................ ................................ ...........................  41 
   
Omnipod  
Horizon™ Prepi[INVESTIGATOR_45860] V2. 3 Confidential  Page | [ADDRESS_253376] to Follow -up ................................ ................................ ..........................  42 
10 SPONSOR REPRESENTATIVES  ................................ ................................ .......................  42 
11 SAFETY  ................................ ................................ ................................ ...............................  42 
11.1  Types of Known Risks and Benefits  ................................ ..............................  42 
11.2  Hypoglycemia/Hyperglycemia  ................................ ................................ ....... 43 
11.3  Adverse Events  ................................ ................................ .............................  43 
11.3.1  Definitions  ................................ ................................ .............................  43 
11.3.2  Reportable Adverse Events  ................................ ................................ ... 45 
11.3.3  Hypoglycemic Events  ................................ ................................ ............  46 
11.3.4  Hyperglycemic/Ketotic Events  ................................ ...............................  46 
11.3.5  Relationship of Adverse Event to Investigational Device  .......................  47 
11.3.6  Severity (Intensity) of Adverse Events  ................................ ...................  [ADDRESS_253377] (DSMB) ................................ ..........................  51 
11.9  Medical Mo nitor ................................ ................................ ............................  52 
12 STATISTICAL CONSIDERATIONS  ................................ ................................ .....................  53 
12.1  Objectives and Endpoints  ................................ ................................ .............  53 
12.1.1  Safety Objective  ................................ ................................ ....................  53 
12.1.2  Primary Effectiveness Ob jective  ................................ ............................  53 
12.1.3  Secondary Effectiveness Objective  ................................ .......................  53 
12.1.4  Secondary Effectiveness Endpoints  ................................ ......................  53 
12.2  Sample Size  ................................ ................................ ................................ . 54 
12.3  Analysis Sets  ................................ ................................ ................................  54 
12.3.1  ITT (Intention to Treat) Analysis Set  ................................ ......................  54 
12.3.2  mITT (modified Intention to Treat) Analysis Set  ................................ ..... 54 
12.3.3  PP (Per -Protocol) Analysis Set  ................................ ..............................  54 
12.4  Analysis of Primary and Secondary Effectiveness Endpoints  ........................  55 
12.5  Additional Data Analyses  ................................ ................................ ..............  55 
12.6  Safety Analyses  ................................ ................................ ............................  56 
12.6.1  Evaluation of Adverse Events  ................................ ................................  56 
12.6.2  Evaluation of Device Deficiencies  ................................ .........................  56 
12.7  Baseline C haracteristics  ................................ ................................ ...............  56 
12.8  General Statistical Methods  ................................ ................................ ..........  56 
12.9  Missing Data  ................................ ................................ ................................ . 57 
12.10  Statistical Software  ................................ ................................ ...................  57 
13 DATA HANDLING AND QUALITY ASSURANCE  ................................ ...............................  57 
13.1  Electronic Case Report Forms (eCRFs)  ................................ ........................  [ADDRESS_253378] Identifiers  ................................ ................................ .........................  58 
   
Omnipod  
Horizon™ Prepi[INVESTIGATOR_45860] V2. 3 Confidential  Page | [ADDRESS_253379] (IRB)  ................................ ................................ ... 59 
14.4  Informed Consent  ................................ ................................ .........................  60 
14.5  Confidentiality  ................................ ................................ ...............................  60 
14.6  Modification of the Protocol  ................................ ................................ ...........  61 
14.7  Protocol Deviations  ................................ ................................ .......................  61 
14.8  Study Reporting Requirements  ................................ ................................ ..... 62 
14.9  Selection of Investigators  ................................ ................................ ..............  62 
14.9.1  Financial Disclosure  ................................ ................................ ..............  62 
14.9.2  Investigator Documen tation  ................................ ................................ ... 62 
14.10  Clinical Site Training  ................................ ................................ .................  63 
14.11  Device Use  ................................ ................................ ...............................  63 
14.12  Device Returns  ................................ ................................ .........................  63 
14.13  Policy for Publicat ion and Presentation of Data  ................................ .........  63 
14.14  Sponsor or Regulatory Agency Termination of the Study  ..........................  64 
REFERENCES  ................................ ................................ ................................ .............................  65 
APPENDIX  ................................ ................................ ................................ ................................ .... 68 
  
   
Omnipod  
Horizon™ Prepi[INVESTIGATOR_45860] V2. 3 Confidential  Page | 8 
PROTOCOL SUMMARY  
Protocol title Prepi[INVESTIGATOR_211500] ™ 
Automated Glucose Control  System in patients with type 1 diabetes  
Protocol ID  G190267  
Purpose  To evaluate the safety and effectiveness of the Omnipod Horizon ™ Automated 
Glucose Control  System in patients with type [ADDRESS_253380] of two phases : 
 
1) 14-day standard therapy phase, followed by ; 
2) 14-day hybrid closed -loop phase  
 
Subjects will be enrolled across 6-8 clinical study sites . The 36 evaluable 
subjects will be comprised of two age cohorts as follows:  
 
• 18 subjects aged 6-13.9 years   
• 18 subjects aged 14-70 years  
Indication  The Omnipod Horizon ™ Automated Glucose Control  System is a single 
hormone insulin delivery system intended for the management of diabetes in 
persons requiring insulin.  Continuous subcutaneous insulin infusion may be 
delivered  by [CONTACT_45907] -defined  settings  (manual mode)  or automatically  adjusted in 
response to feedback from a continuous glucose monitor (CGM).  
 
The Omnipod Horizon ™ System can automatically increase insulin  delivery  
based on CGM sensor glucose values and can decrease or suspend delivery of 
insulin when th e glucose value falls below or is predicted to fall below 
predefined threshold values. The Omnipod HORIZON™ System is 
interoperable with compatible iCGMs  and ACE pumps . 
 
The Omnipod Horizon ™ System is designed to assist patients with diabetes in 
achieving glycemic targets set by [CONTACT_201256].   
Study duration  The study is expected to be completed within 6-month s which includes clinical 
site initiation to completion of all data entry and monitoring procedures . 
Investigational 
device s The Omnipod Horizon ™ Automated Glucose Control  System is comprised of 
the following components:  
• Omni pod Horizon ™ tubeless, insulin delivery  alternate controller enabled 
(ACE) pump  (Pod) with the Horizon ™ algorithm  
• Omnipod Horizon ™ Personal Diabetes Manager (PDM)  which is a 
Samsung J3 locked down Android device that operates  the Omnipod 
Horizon ™ App.  
Non-
investigational, 
commercially 
available devices  • Dexcom G6 - Continuous Glucose Monitoring (CGM) system  
• Contour® Next One blood glucose meter  (Ascensia  Diabetes Care, [ADDRESS_253381], Parsippany, NJ [ZIP_CODE] [LOCATION_003])  
• Precision Xtra ketone meter (Abbott Diabetes Care Inc., [ADDRESS_253382], Alameda, CA [ZIP_CODE] [LOCATION_003])  
   
Omnipod  
Horizon™ Prepi[INVESTIGATOR_45860] V2. 3 Confidential  Page | 9 
Safety objective  To evaluate the safety of the Omnipod Horizon ™ Automated Glucose Control  
System in patients with typ e 1 diabetes   
Primary  safety  
endpoint  Proportion of subjects with serious  device -related adverse events  
Secondary safety 
endpoints  • Proportion of subjects with severe hypoglycemia during hybrid closed -
loop 
• Proportion of subjects with diabetic ketoacidosis (DKA) during hybrid 
closed -loop 
Primary 
effectiveness 
objective  To evaluate the effectiveness  of the Omnipod Horizon ™ Automated Glucose 
Control  System  
Primary 
effectiveness 
endpoints  Percentage of time in range (70-180 mg/dL ) during hybrid closed -loop 
compared to standard therapy  for: 
 
• Target blood glucose ( BG) challenge days (approximately hybrid 
closed -loop days 1 -9) 
• Non-challenge days (approximately hybrid closed -loop days 10-14) 
• Overall (hybrid closed -loop days 1 -14) 
Secondary 
effectiveness 
objective  To evaluate additional glycemic measures of effectiveness of the Omnipod 
Horizon™ Automated Glucose Control  System  
Secondary 
effectiveness 
endpoints  The secondary objective will be evaluated using the following per subject 
endpoints : 
 
• Glucose metrics from system CGM during the hybrid closed -loop phase  
will be compared to the standard therapy phase during the day, 
overnight, and overall:   
 
• Mean glucose  
• % of time in range 70 -180 mg/dL  
• % of time in range  70-140 mg/dL  
• % of time  > 180 mg/dL  
• % of time  ≥ 250 mg/dL  
• % of time  ≥ 300 mg/dL  
• % of time  < 70 mg/dL  
• % of time  < 54 mg/dL  
• Standard deviation  
• Coefficient of variation  
 
• Glucose management indicator (GMI) based on overall mean glucose  
• Percentage of time in hybrid closed -loop as proportion of overall device 
usage time  
• Insulin requirements during the hybrid closed -loop phase will be 
compared to the standard therapy phase:  
 
• Total daily i nsulin  (TDI)  (units, units/kg)  
• Total daily basal insulin (units, units/kg)  
• Total daily bolus insulin (units, units/kg)  
 
   
Omnipod  
Horizon™ Prepi[INVESTIGATOR_45860] V2. 3 Confidential  Page | [ADDRESS_253383] meet all of the following criteria to be included in the study:  
1. Age at time of consent /assent  6-70 years  
2. Subjects aged < [ADDRESS_253384] be living with parent/legal guardian  
3. Diagnosed with type [ADDRESS_253385] 6 months . Diagnosis is  based on 
investigator’s clinical judgment . 
4. Deemed appropriate for pump therapy per investigator ’s assessment  taking 
into account previous history of severe hypoglycemic and hyperglycemic 
events , and other comorbidities  
5. Investigator has confidence that the subject can successfully operate all 
study devices and is capable of adhering to the protocol  
6. Willing to use only the following types of insulin during the study: Humalog, 
Novolog,  Admelog , or Api[INVESTIGATOR_45861]  
7. Must be willing to set target glucose  between  130-150 mg /dL each for 
approximately  72-hours  on predefined days during the hybrid closed -
loop phase   
8. Must be willing to extend their participation into the pi[INVESTIGATOR_211501]  
9. Willing to wear the system continuously throughout the study  
10. A1C <10%  at screening visit  
11. Must be willing to use the Dexcom App on the Omnipod Horizon™ PDM as 
the sole source of Dexcom data (with the exception of the Dexcom Follow 
App) during the hybrid closed -loop phase  
12. Subjects scoring ≥ [ADDRESS_253386] be in an AT&T covered area  
15. Willing and able to sign the Informed Consent Form (ICF) and/or h as a 
parent/guardian willing and able to sign the ICF. Assent will be obtained 
from pediatric and adolescent subjects  aged < 18 years  per State 
requirements.  
 
Exclusion Criteria  
Subjects who meet any of the following criteria will be excluded from the study:  
1. A medical condition, which in the opi[INVESTIGATOR_871], would put the 
subject at an unacceptable safety risk 
2. History of severe hypoglycemia (as defined in Section 11.3.3 ) in the past 6 
months  
3. History of DKA (as defined in Section 11.3.4 ) in the past 6 months , 
unrelated t o an intercurrent illness , infusion set failure  or initial diagnosis  
4. Diagnosed with sickle cell disease  
5. Diagnosed with hemophilia or any other bleeding disorders  
6. Plans to receive blood transfusion over the course of the study  
7. Currently d iagnosed with anore xia nervosa or bulimia  
8. Acute or c hronic kidney disease (e.g. estimated GFR < 45) or currently on 
hemodialysis  
9. History of adrenal insufficiency  
10. Has taken oral or injectable steroids within the past 8 weeks or plans to 
take oral or injectable steroids during the course of the study  
11. Unable to tolerate adhesive tape or has any unresolved skin condition in the 
area of sensor or pump placement  
12. Plans to use  insulin other than U -100 insulin intended for use in the  study 
device during the course of th e study  
   
Omnipod  
Horizon™ Prepi[INVESTIGATOR_45860] V2. 3 Confidential  Page | 11 
13. Use of non-insulin anti -diabetic medication  other than metformin  (e.g. GLP1  
agonist , SGLT2  inhibitor, DPP -4 inhibitor, pramlintide)  
14. Current or known history of coronary artery disease that is not stable with 
medical management, including unstable a ngina, or angina that prevents 
moderate exercise despi[INVESTIGATOR_45862], or a history of myocardial 
infarction, percutaneous coronary intervention, or coronary artery by[CONTACT_45910] 12 months.  
15. For subjects >50 years old or with diabetes duration >20 years , abnormal 
electrocardiogram consistent with increased risk of arrhythmia, ischemia, or 
prolonged QT c interval (> 450 ms)  
16. Thyroid Stimulating Hormone (TSH) is outside of normal range  with 
clinical signs of h ypothyroidi sm or hyperthyroidism  
17. Pregnant or lactating, or is a woman of childbearing potential and not on 
acceptable form of birth control (acceptable includes abstinence, condoms, 
oral/injectable contraceptives, IUD or implant)  
18. Participation in another clinical study  using an investigational drug or device  
within the preceding 30-days or intends to participate during the study 
period   
19. Unable to follow clinical protocol for the duration of the study or is otherwise 
deemed unacceptable to participa te in the study per the investigator’s 
clinical judgment.  
Study schedule 
overview  The study schedule consists of the following two phases:  
 
1) 14-day out patient standard therapy phase  followed by ; 
2) 14-day hybrid closed -loop phase  
 
Following subject screening, enrollment,  and device  training,  subjects wi ll 
commence the outpatient standard therap y phase  of the study .  
 
Current Dexcom G6 CGM users may provide data from a [ADDRESS_253387] therapy phase, subjects will be trained on the 
system and  transition to the hybrid closed -loop phase  initiat ing treatment  with 
the Omnipod Horizon ™ System . For the hybrid closed -loop phase , subjects will 
be divided into two groups : 
 
Group 1:  
 
1. N=[ADDRESS_253388] 2-days  while in a supervised hotel/rental house 
environment  and then transition to 1 2-day outpatient environment  
o N=8 subjects aged 6 -13.9 years  
o N=[ADDRESS_253389] s aged 14 -70 years  
Group 2:  
 
2. N=20 subjects aged 6 -70 years  will participate in the hybrid closed -loop 
phase in a 1 4-day outpatient environment  
o N=10 subjects aged 6 -13.9 years  
o N=10 subjects aged 14 -70 years  
   
Omnipod  
Horizon™ Prepi[INVESTIGATOR_45860] V2. 3 Confidential  Page | [ADDRESS_253390] group of subjects (n=16)  will commence the hybrid closed -loop phase 
in the hotel setting. On study day -3, subjects will transition to the outpatient 
setting for the remaining [ADDRESS_253391] 
completed the 2-day hotel phase, the second group of subjects may commence 
hybrid closed -loop. The second group of subjects (n=20) will use hybrid closed -
loop in the outpatient setting for 1 4-days.  
 
All subjects will participate in target glucose challenges  during the hybrid 
closed -loop phase . In total, all subjects will complete 1 4-days of hybrid closed -
loop control, with approximately 72-hours spent at target blood glucoses levels 
set to  130mg/dL, 140mg/dL and 150mg/dL, respectively.  
 
Clinical site staff will receive alerts through a remote monitoring system during 
the study.  
 
After each subject in the prepi[INVESTIGATOR_211502] [ADDRESS_253392] therapy  (Phase 1 ) and continu ing with the 
pi[INVESTIGATOR_45883] -loop phase (Phase 2).  Remote monitoring will be 
discontinued as each subject enrolls in the pi[INVESTIGATOR_2397].  
 
After [ADDRESS_253393] (DSMB ) will 
convene and if the system is determined to be sa fe, the pi[INVESTIGATOR_211503] -loop phase (Phase 2).  
 
The standard therapy phase (Phase 1) of the pi[INVESTIGATOR_211504].    
 
 
  
   
Omnipod  
Horizon™ Prepi[INVESTIGATOR_45860] V2. 3 Confidential  Page | [ADDRESS_253394]  
   
Omnipod  
Horizon™ Prepi[INVESTIGATOR_45860] V2. 3 Confidential  Page | [ADDRESS_253395]  
 
  
   
Omnipod  
Horizon™ Prepi[INVESTIGATOR_45860] V2. 3 Confidential  Page | [ADDRESS_253396] significant barrier to improved 
glucose control in patients with diabetes.3 A paper by [CONTACT_45911] . al. reported on data 
collected by [CONTACT_941] T1D Exchange and found an annual incidence of 11.8% of one or more 
severe hypoglycemic events defined as a seizure or loss of consciousness. The annual 
incidence of severe hypoglycemic events increased to 18.6% in patients with dia betes 
duration greater than [ADDRESS_253397] of acute and chronic complications 
on the longevity of patients with diabetes. Livingstone et . al. found premature death in a 
Scottish registry of patients with diabetes of 11 years in males and 13 years in females.5 
Lind et . al. found a twofold increase in mortality in a Swedish registry compared with 
age-matched non -diabetic cohorts even in patients with recommended levels of 
glycemic control ( A1C < 7.0%).6The most recent treatment guidelines from the 
American Diabetes Association now recommend that adults with type 1 diabetes should 
aim for target A1C levels of 7.0% and that children and  adolescents should aim for 
target A1C levels of 7.5%.7 These recommendations are equivalent to a mean blood 
glucose of 154 mg/dL in adults and 169 mg /dL in children and adolescents compared 
with mean blood glucose in patients without diabetes of 100 mg/dL or less.[ADDRESS_253398] notably the advent of faster analog insulins, the widespread use of insulin pumps 
and the introduction o f continuous glucose monitoring systems. Despi[INVESTIGATOR_45865], diabetes data registries continue to show that the majority of patients are 
unable to meet recommended glycemic targets with available medication and 
technology. In the 2012  report from the T 1D Exchange  Registry , Beck et . al. found the 
average A1C across all ages greater than 8.0% or, equivalently, greater than 183 
mg/dL and only 30% of patients met the ADA target A1C of 7.0% (adults) and 7.5% 
(children).9 A more recent paper from the T1D Exchange Registry by [CONTACT_45912]. al. 
comparing  the 2016 -2018 cohort with 2010 -2012 cohort indicated that among the 9,657 
   
Omnipod  
Horizon™ Prepi[INVESTIGATOR_45860] V2. 3 Confidential  Page | [ADDRESS_253399] 3 years of diabetes duration in 
2010 -2012, mean HbA1c was higher in the 2016 -2018 cohort . The increase in HbA1c 
over time was predominately seen in adolescents and young adults . The American 
Diabetes Association  (ADA) HbA1c target as of 2018 of < 7.5% for children and 
adolescents was achieved by [INVESTIGATOR_13701] a small percentage of youth < 18 years of age (17%); 
only 21% of adults achieved the ADA treatment goal of < 7.0%.10 
The current dilemma of persistent poor diabetes outcomes despi[INVESTIGATOR_45866], insulin 
pumps and continuous glucose monitoring systems is summarized in the FDA 
Guidance Document on Artificial Pancreas Device Systems: “Even with the aid of these 
devices, maintaining blood glucose concentrations within a suggested optimal range is 
a daily struggle for people living with diabetes mel litus and the risk of hypoglycemia 
associated with attempts at improved glycemic control remains an ever -present 
danger”.11 
Insulet has developed the Omnipod Horizon ™ Automated Glucose Control  System  
(hereafter named  Omnipod Horizon ™ System or Omnipod Horizon ™) which is s imilar 
in function to the systems described in the FDA guidance document dated November 9, 
[ADDRESS_253400] 
of an Omnipod® tubeless , insulin delivery  ACE pump, a Personal Diabetes Manager 
(PDM), and the Dexcom  G6 CGM . The control algorithm will reside  on the Pod.  
This prepi[INVESTIGATOR_211505] ™ System  while in a more closely supervised environment prior to 
commencing the pi[INVESTIGATOR_2397] . Target BG challenges will be conducted to ensure 
exposure to stressors during the study . 
 
2 OMNIPOD HORIZON™ SYSTEM STUDY DEVICE OVERVIEW  
This study will evaluate the safe ty and effectiveness of the Omnipod Horizon ™ System . 
The Omnipod Horizon™ System is a hybrid closed -loop automated insulin delivery  
(AID) system  developed by [CONTACT_45915] .  
2.1 Device Description of the Omnipod Horizon ™ System  
The Omnipod Horizon™ System intended f or commercialization is composed of three 
primary components as shown in Figure 1. 
• Omnipod Horizon™ Controller – Horizon App (PDM) and Algorithm  
• Omnipod Horizon™ ACE Pump  – Pod  
• iCGM  – Dexcom G6  
The Omnipod Horizon ™ System will provide automated insulin delivery when 
connected to CGM . The system is expected to reduce hypoglycemia without incurring 
an unacceptable increase in hyperglycemia and mean glucose. The system is also 
expected to reduce the extent and magnitude of hyperglycemia associated with meals. 
Optim al post-prandial control requires the user to deliver  meal boluses as in current 
open -loop therapy, but the normal operation of the control algorithm will  be expected to  
   
Omnipod  
Horizon™ Prepi[INVESTIGATOR_45860] V2. 3 Confidential  Page | 17 
compensate for mismatched  meal boluses and prevent prolonged hyperglycemia. The 
system  uses a control -to-target strategy that attempts to achieve and maintain a set 
target glucose level.  
 
Figure 1:  System components  of the Omnipod Horizon™ System  
2.1.1. Omnipod Horizon™ Controller ( App and Algorithm ) 
 
The Omnipod Horizon ™ Controller is composed of two parts: the Horizon app lication 
(“app”)  and the model predictive control (MPC) algorithm  on the Pod. The MPC 
algorithm provides insulin micro -boluses once every [ADDRESS_253401] -prandial control will  
require the user to give meal boluses in the same manner as current pump therapy, but 
normal  operation of the MPC algorithm will compen sate for missed meal boluses and 
mitigate prolonged hyperglycemia. The MPC algorithm uses a control -to-target strategy 
that attempts to achieve and maintain  a set target glucose value , thereby [CONTACT_211525]. The MPC algorithm  resides on 
the Pod (Pump) component of the Omnipod® Horizon  System ( similar to the DASH ACE 
pump cleared in K191679 , as described further below ). 
 
The Omnipod Horizon ™ app will be the primary user interface and will be used to start 
and stop a Pod, program basal and bolus calculator settings for Manual Mode  as well 
as program settings specific for Automated Mode  (hybrid closed -loop).  
 
Manual Mode  
 
In Manual Mode , the Horizon ™ System will function equivalently to the Omnipod® 
DASH System, which was first cleared under K180045 , most recently under K191679 . 

   
Omnipod  
Horizon™ Prepi[INVESTIGATOR_45860] V2. 3 Confidential  Page | 18 
This includes  delivering insulin at programmed basal rate s and bolus amounts  with the 
option to set temporary basal profiles. The Omnipod  Horizon ™ Controller will also have 
the ability to function as a sensor augmented pump in Manual Mode , using sensor 
glucose data provided by [CONTACT_45917].  
 
Automated Mode  
 
In Automated Mode , the system will support the use of multiple target glucose values , 
currently intended  to be 110 -150 mg/dL at commercialization , in 10 mg/dL increments. 
The experience for the user will  reflect current setup flows whereby [CONTACT_211526], glucose  targets and bolus calculator 
settings. These in turn will inform the MPC algorithm for insulin dosing  parameters. The 
insulin dosing parameters will be adapted over time based on the total dai ly insulin 
(TDI)  delivered  during each Pod use. A temporary hypoglycemia protection mode ( Hypo 
Protect) may be implemented by [CONTACT_45919] . With Hypo Protect, t he algorithm reduces insulin  delivery and is intend ed for use 
over temporary durations when insulin  sensitivity is expected to be higher , such as 
during exercise.  
 
The Omnipod Horizon ™ System will include two apps  on a locked -down smartphone  
(the Samsung J3) , referred to as  Personal Diabetes Manager ( PDM ): the Horizon App 
and the Dexcom App. The Horizon  App, which will have a similar interface to the 
cleared Omnipod® DASH System ( K191679 ), will allow the  use of large text, graphics, 
and on-screen  instructions to prompt the user through set -up processes. It  will also be 
used to program the user’s custom  basal insulin delivery profile, check the Pod status, 
initiate bolus doses of insulin, make changes to a  patient’s insulin delivery profile, 
handle  system alerts and alarms, and enter Automated Mode .  
 
The Dexcom App  interface is identical to the current app of the interoperable Dexcom 
G6 Continuous Glucose Monitoring  System ( K191450 ) and will provide CGM data, 
alerts, and alarms to the user.  
 
The Horizon App and  Dexcom App will not directly communicate  with one another . 
Instead,  the iCGM transmitter will communicate EGV (estimated glucose values)  
directly to the Pod . The Dexcom  transmitter number must be  entered into the Horizon 
App, and th is information is  sent to the Pod  to allow transmission of EGV . The Pod will 
pair directly to the transmitter to receive  EGV  for the algorithm and  also send s the EGV  
back to the  Horizon App  as shown in Figure 1 . 
 
The Omnipod Horizon ™ Controller provides the ab ility to calculate a suggested bolus 
dose through the use  of the bolus calculator. The bolus  calculator will have the option 
for user -selected population of the EGV , which is communicated to the app via the  Pod. 
This suggested bolus calculation feature is provided as a convenience to the user to aid  
in determining the suggested bolus dose based on ingested carbohydrates, most recent 
sensor  glucose reading  (or blood glucose reading if using fingerstick) , programmable 
correction factor, insulin to carbohydrate ratio, target glucose value and insulin on  board 
(IOB) . IOB is calculated by [CONTACT_45920].  
 
As with the cleared Omnipod® DASH S ystem, Insulet will utilize a proprietary encrypted 
security stack  embedded within the Bluetooth Low Energy ( BLE) communication 
   
Omnipod  
Horizon™ Prepi[INVESTIGATOR_45860] V2. 3 Confidential  Page | 19 
between the Horizon app and Pod. The communication to the  iCGM will use Dexcom’s 
communication protocol. The proprietary securit y stack increases the resilience  of the 
device and improves the ability of the system to be protected in the event of future 
identification of  vulnerabilities in standard communication protocols.  
 
2.1.2. Omnipod Horizon™  ACE Pump  
The Pod component of the O mnipod Horizon™  System  is similar to the Omnipod® 
DASH ACE Pump cleared under K191679 . Compared to the DASH ACE Pump 
(K191679), t he Horizon ™ ACE Pump (Pod) has additional software to optimize 
communication to accept inputs from the iCGM ( initially the Dexcom G6) and the 
Horizon ™ Controller .  The insulin delivery mechanism and the patient and fluid 
contact[CONTACT_45921].  
 
The Pod is a lightweight, self -adhesive device that the user fills with U -100 rapid -acting 
insulin and wears  directly on their body. The Pod delivers insulin into the user’s body 
through a small flexible tube, called a  cannula, based on the commands from the 
compatib le controller. In the Omnipod Horizon ™ System,  the Pod will house the MPC 
algorithm and communicate directly with the iCGM  and the Horizon App . The algorithm 
commands  the Pod’s insulin delivery in the form of micro -boluses based on predicted 
glucose values . Figure 2 below is a representation of the  Pod.  
 
 
Figure 2:  The Pod of the Omnipod Horizon ACE pump  
 
  
2.1.3. iCGM  
The third component of the Omnipod Horizon™ System is the iCGM . The Omnipod 
Horizon™ System will be interoperable with a compatible iCGM, currently the Dexcom 
G6 Continuous Glucose Monitoring System ( K191450 ). The Omnipod Horizon ™ Pod  
will communicate with  the Dexcom G6 via Bluetooth Low Energy ( BLE). Glucose values 
from the Dexcom transmitter will be sent to the MPC algorithm residing on the Pod and 

   
Omnipod  
Horizon™ Prepi[INVESTIGATOR_45860] V2. 3 Confidential  Page | 20 
used in insulin dosing adjustments. The glucose values from the Dexcom transmitter 
will be sent independentl y to the Dexcom App on the controller .  
3 HORIZON ™ DATA PORTAL  
Data are securely uploaded from the PDM to Insulet Cloud by [CONTACT_45922] . Data 
are then transferred from Insulet Cloud to the Horizon Data Portal (HDP), which is a 
platform for data review and management. The  HDP runs on an Amazon -based web 
server . The HDP will provide insights including but not limited to:  time in range, time at 
each  target BG , automated/manual mode comparisons, and time spent in each mode .  
Alerts and alarms trigger ed by [CONTACT_211527].  
 
Investigators  will have access to all uploaded data and be able to view historical trends . 
During the prepi[INVESTIGATOR_2397], the system will provide a means for investigators  to monitor 
live updates of CGM and insulin delivery as well as system alerts and alarms.           
 
 
3.1 Remote Monitoring  
Subjects will be monitored remotely via the HDP alert system during the prepi[INVESTIGATOR_211506] -loop phase to allow for real -time assessment of safety.  
 
Investigators wil l be alerted via text message to prespecified alerts including:  
 
• No data alert for 60 minutes  
• Sensor glucose <55 mg/dL  
• Sensor glucose <70 mg/dL for 20 minutes  
• Sensor glucose >300 mg/dL for [ADDRESS_253402] subjects for follow -up.      
   
4 RESULTS FROM FEASIBILITY STUDIES  
The Omnipod Horizon ™ System has been tested in [ADDRESS_253403] also been published in Diabetes Technology and Therapeutics 13, 14, 
15, 16, 17, 18, 19, 20, 21, 22, 23,29. 
5 STUDY SUMMARY  
5.1 Study Purpose  
The purpose of this study is to assess the safety and effectiveness of the 
Omnipod Horizon ™ System in patients  with type 1 diabetes .     
   
Omnipod  
Horizon™ Prepi[INVESTIGATOR_45860] V2. 3 Confidential  Page | 21 
5.2 Study Design  
This is a  single-arm, multi -center, prospective clinical study . Up to  48 subjects aged 6 -
70 years with type 1 diabetes will be enrolled in the study in order to obtain a minimum 
of 36 evaluable subjects , 18 evaluable subjects  in each age cohort (Table 1:  Cohorts ). 
Subjects will be enrolled across 6-[ADDRESS_253404] identification number .  
The study schedule consists of the following two phases:  
1) 14-day outpatient  standard therapy phase  followed by ; 
2) 14-day hybrid closed -loop phase  
 
Cohorts are defined as  shown in Table 1 : 
Table 1:  Cohorts  
 
 
 
 
 
 
 
 
 
 
Following subject screening, enrollment, and device training, subjects will commence 
the outpatient standard therapy phase of the study.  
 
Current Dexcom G6 CGM users may provide data from a [ADDRESS_253405] therapy phase, subjects will be trained on the system 
and transition to the hybrid closed -loop phase i nitiating treatment with the Omnipod 
Horizon™ System.   
 
Clinical site staff will receive alerts through a remote monitoring system during the 
hybrid closed -loop phase . 
 
For the hybrid closed -loop phase, subjects will be divided into two groups:  
 
 
 
 Cohort  Age Range  N (minimum)  
Adults  14-70 years  18 
Children  6-13.9 years  18 
   
Omnipod  
Horizon™ Prepi[INVESTIGATOR_45860] V2. 3 Confidential  Page | 22 
Group 1:  
 
1. N=[ADDRESS_253406] 2-days  while in a supervised hotel/rental house environment  and 
then transition to 12 -day outpatient environment  
o N=8 subjects aged 6 -13.9 years  
o N=8 subje cts aged 14 -70 years  
 
Group 2:  
 
2. N=20 subjects aged 6 -70 years will participate in the hybrid closed -loop phase in 
a remotely monitored 1 4-day outpatient environment  
o N=10 subjects aged 6 -13.9 years  
o N=[ADDRESS_253407] group of subjects (n=16) will commence  the hybrid closed -loop phase in the 
hotel setting. On study day 3,  subjects will transition to the outpatient setting for the 
remaining [ADDRESS_253408] completed the 2-day 
hotel phase, the second group of subjects may commence hybrid closed -loop. The 
second group of subjects (n=20) will use hybrid closed -loop in the outpatient setting for 
14-days.  It is anticipated that Group [ADDRESS_253409] of existing Dexcom G6 u sers 
(those who were using the Dexcom G6 at the time of screening ), while Group 2 will 
include some existing  Dexcom G6 user s and some non -Dexcom G6 users.  Therefore, 
the primary safety and primary effectiveness endpoints will also be presented by 
[CONTACT_45958] G6 use (users and non -users).  
 
All subjects will participate in target BG challenges during the hybrid closed -loop phase. 
In total, all subjects will complete 1 4-days of closed -loop control, with approximately  72- 
hours spent at target blood glucose levels set to  130mg/dL, 140mg/dL and 150mg/dL, 
respectively.  
 
After each subject in the prepi[INVESTIGATOR_211502]  14-days of hybrid -
closed -loop, they may immediately transition to and enroll in the pi[INVESTIGATOR_211507] ( Phase 1 ) and continu ing with the  pi[INVESTIGATOR_211508] -loop phase 
(Phase 2). Remote monitoring will be discontinued as each subje ct enrolls in the pi[INVESTIGATOR_45880].  
 
After [ADDRESS_253410] (DSMB) will convene and if the 
system is determined to be sa fe, the pi[INVESTIGATOR_211509] -loop phase (Phase 2).     
 
The standard therapy phase (Phase 1) of the pi[INVESTIGATOR_211510] . Figure 3 is a representation of the prepi[INVESTIGATOR_211511].  
  
 
 
   
Omnipod  
Horizon™ Prepi[INVESTIGATOR_45860] V2. 3 Confidential  Page | 23 
 
Figure 3:  Horizon Prepi[INVESTIGATOR_211512]™ Prepi[INVESTIGATOR_45860] V2. 3 Confidential  Page | 24 
Table 2:  Schedule of Assessments  
Assessment Schedule  Screening  ST1 ST2 Hybrid Closed -Loop (HCL)  EWa 
  Phase 1 Phase 2   
Visit Number  1 2 3 4 5 6 7 8 9 10 UVb   
Study Day/Visit Window  -30d to   
HCL start  -14d to 
HCL 
start  -1d to 
HCL 
start  1 2 3 4 
+1d 7 
±1d 10 
±1d 14 
+2d N/A   
Group 1i: 
2-day Hotel  + 
12-days Outpatient  
Hotel (H), Telephone (T) or Office (O) Visit  O O O H H H T/Of T/Of T/Of T/Of T/Of O 
Group 2i: 
14-days Outpatient  
Hotel (H), Telephone (T) or Office (O) Visit  O O O O T/Of T/Of T/Of T/Of T/Of T/Of T/Of O 
Laboratory Assessments  
A1C X                       
TSH X                       
Creatinine Level  X                       
Pregnancy Test  X     X                 
Clini cal Assessments  
Informed Consent  X                       
Confirm Eligibility  X                       
Medical History (including 
demographics)  X                       
Conc omitant medications  X Xe   Xe Xe Xe Xe Xe Xe Xe Xe Xe 
Average total daily insulin (~ 7 days)   X   X                 
Average total basal insulin (~ 7 days)   X   X                 
Average total bolus insulin (~ 7 days)   X   X                 
Pump settings/MDI dosing    X   X                 
   
Omnipod  
Horizon™ Prepi[INVESTIGATOR_45860] V2. 3 Confidential  Page | 25 
Assessment Schedule  Screening  ST1 ST2 Hybrid Closed -Loop (HCL)  EWa 
  Phase 1 Phase 2   
Visit Number  1 2 3 4 5 6 7 8 9 10 UVb   
Study Day/Visit Window  -30d to   
HCL start  -14d to 
HCL 
start  -1d to 
HCL 
start  1 2 3 4 
+1d 7 
±1d 10 
±1d 14 
+2d N/A   
Height  X                 X   X 
Weight  X                 X   X 
Vital signs  X                 X X X 
Electrocardiogramc (if applicable)  X                       
Adverse events        Xe Xe Xe Xe Xe Xe Xe Xe Xe 
Questionnaires  
See Table  3 for specific questionnaires  X X                X   X 
Study Devices  
Training on Glucagon administration 
and information on treatment of 
hypo/hyperglycemia    X                     
Remote monitoring 
initiation/discontinuation        X           X   X 
Study device training    Xg   Xh                 
Dispense/Return  
BG/Ketone meter, and CGM    X               Xd   X 
QC testing of BG/Ketone meter by [CONTACT_3725]    X                     
CGM sensor placement (as needed 
throughout)    X                     
Assess CGM usage and data criteria 
has been met  Xj   X                   
Dispense/Return Horizon System        X           Xd   X 
Complaints/device deficiencies        Xe Xe Xe Xe Xe Xe Xe Xe Xe 
Device uploads/Data review        X X X X X X X X X 
   
Omnipod  
Horizon™ Prepi[INVESTIGATOR_45860] V2. 3 Confidential  Page | 26 
Abbreviations:  S=Screening; ST1=Standard Therapy Day One; ST2=Standard Therapy Day Two; HCL=Hybrid Closed -loop; EW=Early 
Withdrawal; QC=Quality Control Testing; Hotel/Rental House=HRH; UV=Unscheduled Visit  
aEarly  withdrawal visit will only be conducted for any subjects that started but did not complete the full study to include standard  therapy 
and the hybrid closed -loop  phase.   
bUnscheduled visits will serve as extra study visits, if needed  
cElectrocardiogram required for subjects >50 years old or with diabetes duration >[ADDRESS_253411] is not extending their participation into the pi[INVESTIGATOR_211513] "T/O" can either be conducted in person at the clinical site or over the telephone . Visits identified as "O" can only be 
conducted in person at the clinical site  
gStudy device training for the CGM, blood glucose and ketone meters  
hStudy de vice training for the Omnipod Horizon™ System  
iSubjects  deemed exempt from wearing the study CGM for [ADDRESS_253412] 2 
jAssessment of CGM criteria during screening applies to current Dexcom G6 users only  
 
  
   
Omnipod  
Horizon™ Prepi[INVESTIGATOR_45860] V2. 3 Confidential  Page | 27 
 
Table 3:  Questionnaires  
Visit    Age Groups  
Adult  Teen  
(ages 12 -18) Caregiver -Teen  
(ages 12 -18) Pediatric  
(ages 8-11.9) Caregiver -Pediatric  
(ages 6 -11.9) 
Screening  Clarke  Clarke  n/a n/a Clarke  
Visit 2  WHO -5 
EQ-5D 
T1DDS  
DTSQ s 
Hypo glycemia  
Conf idence  Scale  
HABS  
PSQI  
IDSS (T1)  
SUS WHO -5 
EQ-5D 
PAID -Teen  
Hypo glycemia  
Conf idence  Scale  
PSQI  
SUS WHO -5 
P-PAID -Teen  
Hypo glycemia  
Conf idence Scale  
PSQI  
DTSQ s 
IDSS (T1)  EQ-5D-Y 
PAID -Child  WHO -5 
P-PAID -Child  
Hypo glycemia  
Conf idence  Scale  
PSQI  
DTSQ s 
IDSS (T1)  
SUS 
Final 
Visit /Early 
Withdrawal  WHO -5 
EQ-5D 
T1DDS  
DTSQ c 
Hypo glycemia  
Conf idence  Scale  
HABS  
PSQI  
IDSS (T1)  
SUS 
INSPI[INVESTIGATOR_21392] -Adult  
Clarke  
HF Questionnaire  WHO -5 
EQ-5D 
PAID -Teen  
Hypo glycemia  
Conf idence  Scale  
PSQI  
SUS 
INSPI[INVESTIGATOR_21392] -Youth  
Clarke  
HF Questionnaire  WHO -5 
P-PAID -Teen  
Hypo glycemia  
Conf idence  Scale  
PSQI  
DTSQ c 
IDSS (T1)  
INSPI[INVESTIGATOR_21392] -Parent  EQ-5D-Y 
PAID -Child  
INSPI[INVESTIGATOR_21392] -Youth  WHO -5 
P-PAID -Child  
Hypo glycemia  
Conf idence  Scale  
PSQI  
DTSQ c 
IDSS (T1)  
SUS 
INSPI[INVESTIGATOR_21392] -Parent  
Clarke  
HF Questionnaire  
 
   
Omnipod  
Horizon™ Prepi[INVESTIGATOR_45860] V2. 3 Confidential  Page | 28 
6 OBJECTIVES AND ENDPOINTS  
6.1 Safety Objective  
The safety objective of this study is to evaluate the safety of the Omnipod 
Horizon ™ System  in patients with type 1 diabetes . 
6.1.1  Primary Safety Endpoint  
Proportion of subjects with serious device -related adverse events . 
 
6.1.2  Secondary Safety Endpoints  
• Proportion of subjects with severe hypoglycemia during hybrid closed -
loop 
• Proportion of subjects with diabetic ketoacidosis (DKA) during hybrid 
closed -loop 
  
6.2 Primary Effectiveness Objective  
The primary effectiveness objective of this study is to evaluate the effectiveness  of 
the Omnipod Horizon ™ System . 
 
6.2.1  Primary Effectiveness Endpoint  
Percentage  of time in range (70-180 mg/dL ) during  hybrid closed -loop compared 
to standard therapy  for: 
 
• Target BG challenge days (approximately hybrid closed -loop days 1 -9) 
• Non-challenge days (approximately hybrid closed -loop days 10-14) 
• Overall (hybrid closed -loop days 1 -14) 
 
6.3 Secondary Effectiveness Objective  
To evaluate additional glycemic measures of effectiveness of the Omnipod 
Horizon™ System in patients with type [ADDRESS_253413] 
endpoi nts:   
• Glucose metrics from system CGM during the hybrid closed -loop phase will 
be compared to the standard therapy phase during the day, overnight, and 
overall:  
 
• Mean glucose  
• % of time in range 70 -180 mg/dL  
• % of time in range 70 -140 mg/dL  
• % of time > 180 mg/dL  
   
Omnipod  
Horizon™ Prepi[INVESTIGATOR_45860] V2. 3 Confidential  Page | 29 
• % of time ≥ 250 mg/dL  
• % of time ≥ 300 mg/dL  
• % of time < 70 mg/dL  
• % of time < 54 mg/dL  
• Standard deviation  
• Coefficient of variation  
 
• GMI based on overall mean glucose  
• Percentage of time in hybrid closed -loop as proportion of overall device 
usage time  
• Insulin requirements during the hybrid closed -loop phase will be compared to 
the standard therapy phase:  
 
• Total daily insulin (TDI) (units, units/kg)  
• Total daily basal insulin (units, units/kg)  
• Total daily bolus insulin (units, units/kg)  
 
 
[ADDRESS_253414] 6 months  and are appropriate for pump therapy per 
investigator ’s assessment . Potential subject s will be selected at each clinical study site 
and screened accordingly. Clinical study sites will be advised  to: 
• Recruit subjects using insulin aspart, lispro, and glulisine also known as 
Humalog, Novolog, Admelog, and Api[INVESTIGATOR_27976]  
• Recruit at least 20% of subjects using MDI  
Every  effort will be made to establish eligibility of the patient  prior to enrollment . Only 
patients  who appear to meet all eligibility criteria will be enrolled in the study.  Subject  
eligibility will be confirmed by [CONTACT_45928] a screening  visit at the clinical site. 
Blood draws will be collected as required to demonstrate study eligibility as noted 
below.  Laboratory results  within the last [ADDRESS_253415] participated in the prepi[INVESTIGATOR_211514].  
7.1 Visit 1  
Visit 1 will be conducted in person at the clinical study site . This visit will assess 
eligibility and will include:  
 
• Signing of informed consent/assent  
• Review of inclusion/exclusion criteria  
• Screening assessments  performed following Table 2:  Schedule of 
Assessments  
• Enrollment  
   
Omnipod  
Horizon™ Prepi[INVESTIGATOR_45860] V2. 3 Confidential  Page | 30 
 
Informed Consent /Assent  
 
Subjects who appear to meet the eligibility criteria will be asked to sign an 
Informed Consent Form (ICF) approved by [CONTACT_45929] (IRB) for participation in the study . A parent/guardian must sign the ICF for 
subjects <18 years of age. Assent will also be obtained from subjects aged <18 
years per State requirements.  Failure to provide informed consent /assent  will 
render the subject ineligible for the study.  
Subjects must also have a signed HIPAA ( Health Insurance Portability and 
Accountability Act)  release of protected health information (PHI). The release may 
be a stand -alone document or part of the informed  consent.  
After informed consent /assent  is obtained, a subject identification number will be 
issued to uniquely identify each subject . The unique identifier will be used to 
identify the subject throughout the study and will be used for all source documents 
and electronic Case Report Forms (eCRFs).  Subjects will retain the same subject 
identification number if they continue in the pi[INVESTIGATOR_2397].  
Inclusion Criteria   
Subject s must meet all of the following criteria in order to be enrolled in the stud y: 
1. Age at time of consent 6 -70 years  
2. Subjects aged < [ADDRESS_253416] be living with parent/legal guardian  
3. Diagnosed with type [ADDRESS_253417] 6 months. Diagnosis is based on 
investigator’s clinical judgment  
4. Deemed appropriate for pump therapy per inv estigators assessment taking 
into account previous history of severe hypoglycemic and hyperglycemic 
events, and other comorbidities  
5. Investigator has confidence that the subject can successfully operate all 
study devices and is capable of adhering to the pr otocol  
6. Willing to use only Humalog, Novolog, Admelog  or Api[INVESTIGATOR_211515]  
7. Must be willing to set target glucose between 130 -150 mg/dL each for 
approximately  72-hours on predefined days during the hybrid closed -loop 
phase  
8. Must be willing to extend their participation into the pi[INVESTIGATOR_211516]  
9. Willing to wear the system continuously throughout the study  
10. A1C <10%  at screening visit  
11. Must be willing to use the Dexcom App on the Omnipo d Horizon PDM as the 
sole source of Dexcom data (with the exception of the Dexcom Follow App) 
during the hybrid closed -loop phase  
12. Subjects scoring ≥ [ADDRESS_253418] be in an AT&T covered area  
15. Willing and able to sign the Informed Consent Form (ICF) and/or has a 
parent/guardian willing and able to sign the ICF. Assent will be obtained from 
   
Omnipod  
Horizon™ Prepi[INVESTIGATOR_45860] V2. 3 Confidential  Page | 31 
subjects  aged < [ADDRESS_253419] s who meet any of the following criteria will be excluded from the study:  
1. A medical condition, which in the opi[INVESTIGATOR_871], would put the 
subject at an unacceptable safety risk 
2. History of severe hypoglycemia  (as defined in Section 11.3.3 ) in the past 6 
months  
3. History of D iabetic Ketoacidosis (DK A) (as defined in Section 11.3.4 ) in the 
past 6 months , unrelated to an intercurrent illness , infusion set failure  or 
initial diagnosis  
4. Diagnosed with sickle cell disease  
5. Diagnosed with hemophilia or any other bleeding disorders  
6. Plans to receive blood transfusion over the course of the study  
7. Curren tly diagnosed with anorexia nervosa or bulimia  
8. Acute or c hronic kidney disease (e.g. estimated GFR < 45) or currently on 
hemodialysis  
9. History of adrenal insufficiency  
10. Has taken oral or injectable steroids within the past 8 weeks or plans to take 
oral or in jectable steroids during the course of the study  
11. Unable to tolerate adhesive tape or has an y unresolved skin condition in the 
area of sensor or pump placement  
12. Use of insulin other than U -100 insulin intended for use in the pump  
13. Use of  non-insulin anti -diabetic medication other than metformin  (e.g. GLP1 
agonist, SGLT2 inhibitor, DPP -4 inhibitor, pramlintide)  
14. Current or known history of coronary artery disease th at is not stable with 
medical management, including unstable angina, or angina that prevents 
moderate exercise despi[INVESTIGATOR_45862], or a history of myocardial 
infarction, percutaneous coronary intervention, or coronary artery by[CONTACT_45910] 12 months.  
15. For subjects > 50 years old or with diabetes duration > 20 years, a bnormal 
electrocardiogram consistent with increased risk of arrhythmia, ischemia, or 
prolonged QT c interval (> 4 50 ms)  
16. Thyroid Stimulating Hormone (TSH)  is outside  of normal range with 
clinical signs  of hypo thyroidism  or hyp erthyroidism  
17. Pregnant or lactating, or is a woman of childbearing potential and not on 
acceptable form of birth control (acceptable includes abstinence, condoms, 
oral/injectable contraceptives, IUD or implant)  
18. Participati on in another clinical study using an investigational drug or device  
within the preceding 30 -days or intends to participate during the study period    
19. Unable to follow clinical protocol for the duration of the stud y or is otherwise 
deemed unacceptable to participate in the study per the investigator’s clinical 
judgment  
Screening  Assessments  
Subject s who have signed the informed consent and appear to meet the eligibility 
criteria will continue to the s creening assess ments which will be performed at the 
clinical study site .  
   
Omnipod  
Horizon™ Prepi[INVESTIGATOR_45860] V2. 3 Confidential  Page | [ADDRESS_253420] be completed within 30-days  prior to the start date 
of the hybrid  closed -loop phase  (assessments  do not need to be completed on the 
same day)  and include the following : 
• Medical history (including  prior and current medical cond itions and surgical 
history ) 
• Demographics (age, gender, race)  
• A1C*  
• Thyroid Stimulating Hormone (TSH) level  (local laboratory)  
• Creatinine level  (local laboratory)  
• Pregnancy test for women of childbearing potential  
• Review of c oncomitant medications  
• Height  
• Weight  
• Assessment of v ital signs  
• Electrocardiogram (if applicable , see exclusion criteria 15 ) 
• Questionnaire  (Table 3:  Questionnaires ): 
o Clarke  
▪ Used to assess impaired awareness of hypoglycemia  
• For Dexcom G6 users, a ssessment of whether subjects have met the CGM 
usage and data criteria  to participate in an abbreviated standard therapy 
phase (Visit 2 only) per  Table 2:  Schedule of Assessments  
o At least 80% CGM use (11.2 -days) during any consecuti ve [ADDRESS_253421] 30 -days and  
o ≥ 2,016 CGM values during the 14 -days  
 
*Clinical sites will send the b lood specimens for A1C to a NGSP (National 
Glycohemoglobin Standardization Program) certified central  laboratory . A point of 
care (POC) A1C may be used to determine eligibility.   
The Clarke Questionnaire will be administered during the screening visit. Subjects 
scoring ≥ [ADDRESS_253422] will not continue in the prepi[INVESTIGATOR_2397]. No  
additional study assessments will be required. The reason for study exit  will be 
clearly documented.  
   
Omnipod  
Horizon™ Prepi[INVESTIGATOR_45860] V2. 3 Confidential  Page | [ADDRESS_253423] therapy assessments are 
completed per Visit 2  – see Table 2:  Schedule of Assessments .  
During the standard therapy phase, subject s will be asked to perform the following:  
• Manage their diabetes at home per their usual routi ne 
• Administer meal boluses per their usual  dosing routine  
• Change their sensor if a sensor fails, or as needed  
• Calibrat e their CGM , if required, per the manufacturer’s instructions   
• Monitor their c api[INVESTIGATOR_30135] (BG) per usual routine  
• Give meal boluses. The timing of the bolus delivery will be  per each subject’s 
typi[INVESTIGATOR_45876] . 
Extending standard therapy past [ADDRESS_253424] 
profile:  
 
• Current Dexcom G6 users   
• Non-G6 users  
• Pump Naïve users  
 
Current Dexcom G6 Users  
 
Current Dexcom G6 users will be required to participate in the assessments required as 
part of standard therapy but may be exempt from wearing the study CGM for 14 -days if 
the followi ng criteria are met:  
 
• Willing to provide [ADDRESS_253425] 30 -days  
• Meet the success criteria of 80% CGM use during any consecutive 14-days in the 
past 30 -days  
• Must have ≥ 2,[ADDRESS_253426] 
therapy phase consistent with the require ments for non-G6 users . 
 
Subjects deemed exempt from wearing the study CGM  for 14 -days  will be eligible to 
immediately commence the hybrid closed -loop phase.   
 
Non-G6 Users  
   
Omnipod  
Horizon™ Prepi[INVESTIGATOR_45860] V2. 3 Confidential  Page | [ADDRESS_253427] s of wearing a  
cleared Omnipod® DASH System with the Pod filled with saline to simulate pump 
therapy. This would enable subjects to familiarize themselves with the basic concepts of 
basal and bolus insulin delivery as well as provide the experience of wearing an on -
body device prior to their participation in the  hybrid closed -loop phase , if they choose to 
do so . This is optional and not required.  
8.[ADDRESS_253428] therapy phase. All 
scheduled assessments will be performed according to Table 2:  Schedule of 
Assessments . This visit will include : 
• Review of concomitant medications  
• Average total daily insulin (approximately over the past 7 days)  
• Average total daily basal insulin (approximately  over the past 7 days)  
• Average total daily bolus insulin (approximately over the past 7 days)  
• Review pump settings/MDI dosing  
• Completion of questionnaires  (see Table 3:  Questionnaires  for specific 
requirements by [CONTACT_551]) : 
• WHO -5 
o Used to measure current mental well -being  
• EQ-5D 
o Used to measure quality of life  
• T1DDS  
o Used to measure four critical dimensions of distress  
• DTSQ s  
o Used to measure  satisfaction with diabetes treatment regimens  
• Hypo glycemia  Conf idence Scale  
o Used to measure  hypoglycemia unawareness, hypoglycemia 
frequency, severity and impact  
• HABS  
o Used to measure  critical dimensions of hypoglycemia relat ed 
concerns and confidence  
• PSQI  
o Used to measure  sleep disturbance and usual sleep habits  
• IDSS (T1)  
o Used to measure  patient satisfaction with their devices and impact 
on quality of life  
• SUS 
   
Omnipod  
Horizon™ Prepi[INVESTIGATOR_45860] V2. 3 Confidential  Page | 35 
o Used to measure usability of a system  
• PAID -(Teen, Child)  
o Measures diabetes -related burden  
• Training on Glucagon  administration  and information on treatment of 
hypo/hyperglycemia   
• All subjects are required to have access to glucagon and receive 
training on how to deliver the medication  
• Study device training per m anufacturer’s instructions  (CGM  - blinded , BG, 
and ketone meters)  
• Dispensing of CGM  (blinded  for non -G6 users ), BG, and ketone meter  
• QC testing of BG and ketone meter  
• Must pass as least one level of quality control testing prior to 
dispensing  
• CGM sensor pl acement (if applicable)   
• Approved anatomical locations for CGM sensor placement will be 
reinforced as well as the importance of using approved locations  
During this visit, s ubjects will be dispensed the following supplies : 
• Dexcom transmitter  
• Dexcom receiver  
• Dexcom sensors  
• Contour® Next One b lood glucose meter  
• Contour® Next One b lood glucose meter test strips  
• Contour® Next One b lood glucose meter control solution  
• Lancets  
• Precision Xtra  blood ketone meter  
• Precision Xtra  blood ketone meter test strips  
• Precision Xtra  blood ketone meter control solution  
 
Subjects will be provided, by [CONTACT_779], information regarding treatment of 
hypoglycemia and hyperglycemia including sick day management and emergency 
management of severe hypoglycemia and diabetic ketoacidosis. Subjects will be 
given contact [CONTACT_45931] .     
If a subject is on MDI, the investigator will advise the subject on the treatment 
regimen to reduce insulin depending on the insulin action profile of injected doses  
prior to the commencement of the hybrid closed -loop phase . MDI subjects will be 
required to ke ep a log to record daily doses of insulin during the standard therapy 
phase.  
8.2 Visit 3  
Visit 3  will be conducted in person at the clinical study site  one (1) day prior to the 
start of the hybrid closed -loop phase . All scheduled assessments will be 
performed according to Table 2:  Schedule of Assessments . This visit will include  
assessment of whether subjects have met the CGM usage and data criteria . 
 
Prior to the commencemen t of the hybrid closed -loop phase, subjects must meet 
the following criteria:  
   
Omnipod  
Horizon™ Prepi[INVESTIGATOR_45860] V2. 3 Confidential  Page | [ADDRESS_253429] 80% CGM use (11.2 -days) during any consecutive 14-days in the 
past 30 -days  and 
o ≥ 2,[ADDRESS_253430] therapy phase and after all assessments are performed according to  Table 2:  
Schedule of Assessments .   
During the hybrid closed -loop phase, subjects will be asked to  do the following:  
• Adjust pump and CGM parameters to optimize their insulin therapy in 
collaboration with the recommendations fr om the clinical study staff  
• Follow their pre -exercise management such as insulin reduction for meal 
boluses, consumption of snacks, or adjusting their insulin delivery settings  
• Treat themselves per their usual routine if they become hypoglycemic or 
hypergl ycemic or have symptoms of either at any time during the study  
• Consume meals and snacks of their own choosing. Subjects will be encouraged 
to estimate the grams of carbohydrates for each meal or snack per their usual 
routine. The estimate should be entered  into the meal bolus calculator.  
• Administer meal boluses per their usual  dosing routine  
• Participate in target BG challenges as specified  
• Change their CGM per manufacturer’s instructions or sooner if necessary  
• Change the Pod at least once every 72 hours  
• Com plete questionnaires (Table 3:  Questionnaires ) 
 
Subjects will have scheduled follow -up visits according to Table 2:  Schedule of 
Assessments  and complete questionnaires according to Table 3:  Questionnaires . Visits 
will be conducted either in the hotel/rental house environment, in person at the clinical 
study site or over the telephone . Subjects may also choose to use email or text as a 
substitut e for their scheduled telephone visit.    
 
The duration of the hybrid closed -loop phase will last 1 4-days.  
 
9.1 Target BG  Challenges  
All subjects will take part in the target blood glucose (BG) challenges  (Table 4:  
Target BG Challenges ). Following the commencement of the hybrid closed -loop 
phase , subjects will be required to set their target BG to 130 mg/dL for 
approximately  72 hours  for days 1 -3, 140 mg/dL for days 4 -6, and 150 mg/dL for 
   
Omnipod  
Horizon™ Prepi[INVESTIGATOR_45860] V2. 3 Confidential  Page | 37 
day 7 -9 according to Table 4:  Target BG Challenges . Upon completion of the 3 
target BG challenges ( 130 mg/dL , 140  mg/dL, and 150 mg/dL), subjects may 
choose their desired target BG between 110 -150 m g/dL for the remainder of the 5-
days of the hybrid closed -loop phase.  
 
Table 4:  Target BG Challenges  
  Days  
1 2 3 4 5 6 7 8 9 10-14 
Target  
BG 130 mg/dL  140 mg/dL  150 mg/dL  110-150 
mg/dL  
 
These settings will be reviewed by [CONTACT_211528] e requirement s are met. If the requirements 
have not been met, clinical staff may request the subject adjust their setpoint until 
the requirements are met  unless there are safety concerns . 
 
9.2 Hotel/Rental House Environment  
The subset of subjects participating in the hotel/rental ho use environment will be 
encouraged to eat meals of their own choosing, unrestricted in carbohydrates, and 
to engage in moderate intensity exercise for a minimum of 1 hour per day.  
Moderate intensity exercise is defined using the CDC guidelines12: 
Table 5:  CDC Guidelines12 for Moderate Intensity Exercise  
 Children and 
Adolescents  Adults  Older Adults  
Moderate Intensity 
Activities  Brisk walking  
Bicycling  
Hiking  
Catching/throwing  Walking/jogging 2.5 
miles per hou r 
Bicycling  
Aerobics  Walking/hiking  
Jogging  
Bicycling  
Aerobics  
 
9.3 Visit 4 
Visit 4 represents the  commencement of the hybrid closed -loop phase . For 
subjects in Group 1, t his visit will be conducted  at the hotel/rental house . For 
subjects in Group 2 this visit will be conducted  at the clinical study site . All 
scheduled assessments will be performed according to  Table 2:  Schedule of 
Assessments . This visit will include:  
• Pregnancy test for women of childbearing potential  
• Review of concomitant medications  
• Average total daily insulin (approximately over the past 7 days)  
• Average total dai ly basal insulin (approximately over the past 7 days)  
• Average total daily bolus insulin (approximately over the past 7 days)  
   
Omnipod  
Horizon™ Prepi[INVESTIGATOR_45860] V2. 3 Confidential  Page | 38 
• Pump settings/MDI dosing  
• Assessment of AEs  
• Remote monitoring initiation  
• Omnipod Horizon™ System device training conducted by [CONTACT_31610] d clinical 
site staff  
o Subjects will be trained on operating Omnipod Horizon™ in both 
Manual and Automated Modes.  
o This will include first time device set -up with entry of basal profile, bolus 
calculator settings with insulin:carbohydrate ratio, target glucose and 
correction factor.  
o The Pod will be filled with the subject’s own U -100 rapid -acting insulin 
and placed on  body. Subjects will also be trained on use of Dexcom G6 
CGM, regardless of previous experience, setting up low (recommended 
to be 70 mg/dL  or higher ) and high glucose alerts (recommended to be 
300 mg/dL  or lower ) and entering transmitter serial number int o the 
Horizon App.  
o In addition, Omnipod Horizon™ has a novel bolus calculator feature 
that incorporates both the CGM value and trend into the suggested 
bolus amount. In general, if the CGM values are trending up or down, 
the calculator will add or subtrac t insulin from the suggested bolus 
amount to help keep BGs within target ran ge. 
• Dispense Omnipod Horizon ™ System  
• Complaints/device deficiencies for CGM, BG and ketone meter  
• Device uploads for CGM, BG and ketone meter  
• Data review by [CONTACT_30223]  
• Removal of the subject’s personal insulin pump (if applicable)  
o Prior to commencing hybrid closed -loop, the subject’s personal insulin 
pump will be removed, if applicable. Investigators may use the Insulet -
provided Patient Therapy Order Form (PTOF) as a guide to transition 
subjects from MDI to pump therapy (Appendix).  
At the conclusion of the training  and completion of assessments , each subject will 
initiate their treatment marking their commencement of the hybrid closed -loop 
phase.  
9.4 Visit 5 
Visit 5 will be conduc ted in the hotel/rental house for subjects in Group 1, and 
over the telephone for subjects in Group 2 . All scheduled assessments will be 
performed according to  Table 2:  Schedule of Assessments . This visit will include :  
• Review of concomitant medications  
• Assessment of AEs since last visit  
• Complaints/device deficiencies such as occlusion alarms and system 
hazard alarms since last visit  
• Device uploads for BG and ketone meter  
• Data review by [CONTACT_45937]™ Prepi[INVESTIGATOR_45860] V2. 3 Confidential  Page | 39 
9.5 Visit 6  
Visit 6  will be conducted in the hotel/rental house for subjects in Group 1, and 
over the telephone  for subjects in Group 2 . All scheduled assessments will be 
performed according to  Table 2:  Schedule of Assessments . This visit will include:  
 
• Review of concomitant medications  
• Asse ssments of AEs since last visit  
• Complaints/device deficiencies such as occlusion alarms and system 
hazard alarms since last visit  
• Device uploads for BG and ketone meter  
• Data review by [CONTACT_211529] 1 will be discharged home on  study day 3 (V isit 6).   
 
During each visit, subjects will be reminded to set the appropriate target BG on the 
appropriate day as applicable.  
 
9.6 Visit s 7, 8 and  9 
Visit s 7 through Visit 9 will be conducted over the telephone . All scheduled 
assessments will be performed according to  Table 2:  Schedule of Assessments . 
These visits will include : 
 
• Review of concomitant medications  
• Assessment of AEs since last visit  
• Complaints/device deficiencies such as occlusion alarms and system 
hazard alarms since last visit  
• Device uploads for BG and ketone meter (if visit is conducted at the clinical 
study site)  
• Data review by [CONTACT_211530] 
• Ensuring at least 72 hours of data collected at designated target BG levels 
per Table 4 – Target BG Challenges.  
 
During each visit, s ubjects will be reminded to set the  appropriate  target BG on the 
appropriate day as applicable .  
 
9.7 Visit 10 (End of Study ) 
Visit 10 will be conducted in person at the clinical study site . All scheduled 
assessments will be performed according to  Table 2:  Schedule of Assessments . 
If the subject has not experienced any serious adverse events , and continue to 
meet eligibility requirements,  the subject will be deemed eligible to participate in  
the pi[INVESTIGATOR_2397]. This visit will conclude their participation in the prepi[INVESTIGATOR_2397]. 
This visit will include : 
 
• Review of concomitant medications  
• Height  
• Weight  
   
Omnipod  
Horizon™ Prepi[INVESTIGATOR_45860] V2. 3 Confidential  Page | 40 
• Assessment of vital signs  
• Assessment of AEs since last visit  
• Completion of questionnaires  (see Table 3:  Questionnaires  for specific 
requirements by [CONTACT_551]) : 
• WHO -5 
• EQ-5D 
• T1DDS  
• DTSQ c  
• Hypo glycemia  Conf idence  Scale  
• HABS  
• PSQI  
• IDSS (T1)  
• SUS 
• PAID -(Teen, Child)  
• INSPI[INVESTIGATOR_21392] -(Adult, Youth, Parent)  
▪ Used to measure a caregiver’s experience of the support they 
receive  
• Clarke  
• Human Factors (HF)  Questionnaire  
▪ Measures trust in the Horizon ™ System  
• Discontinuation of remote monitoring  
• Return study devices (Omnipod Horizon™ System, CGM, BG and ketone 
meters if not extending into pi[INVESTIGATOR_2397])  
• Complaints/device deficiencies such as occlusion alarms and system 
hazard alarms since last visit  
• Device uploads for BG and ketone meter  
• Data review by [CONTACT_211531][INVESTIGATOR_2397], they  will return 
their study devices to the site and their participation in the study will end.  
 
9.8 Unscheduled Visits  
Aside from scheduled visits, subjects  may require an unscheduled visit either by 
[CONTACT_211532] n at the clinical study site . All scheduled assessments will be 
performed according to  Table 2:  Schedule of Assessments . This visit will include, 
at a minimum : 
 
• Review of concomitant medications  
• Assessment of vital signs (if visit is conducted at the clinical study site)  
• Assessment of AEs since last visit  
• Complaints/device deficiencies such as occlusion alarms and system 
hazard alarms since last visit  
• Device uploads for BG and ketone meter (if visit is conducted at the clinical 
study site)  
• Data review by [CONTACT_45945].  
 
   
Omnipod  
Horizon™ Prepi[INVESTIGATOR_45860] V2. 3 Confidential  Page | [ADDRESS_253431]  may withdraw early from the study at any time  for any reason . Upon 
withdrawal, assessments will be performed following the Table 2:  Schedule of 
Assessments . The investigator may also terminate a subj ect’s participation in the 
study if it is in the best interest of the subject or if the Sponsor or local regulatory 
agency (e.g., FDA) terminates the study.  
 
The Early Withdrawal visit will include:  
 
• Review of concomitant medications  
• Height  
• Weight  
• Assessment of vital signs  
• Assessment of AEs since last visit  
• Completion of questionnaires  (see Table 3:  Questionnaires  for specific 
requirements by [CONTACT_551]) : 
• WHO -5 
• EQ-5D 
• T1DDS  
• DTSQ c  
• Hypo glycemia  Conf idence  Scale  
• HABS  
• PSQI  
• IDSS (T1)  
• SUS 
• PAID -(Teen, Child)  
• INSPI[INVESTIGATOR_21392] -(Adult, Youth, Parent)  
• Clarke  
• Human Factors (HF)  Questionnaire  
• Discontinuation of remote monitoring  
• Return all study devices  
• Complaints/device deficiencies such as occlusion alarms and system 
hazard alarms since last visit  
• Device uploads for BG and ketone meter  
• Data review by [CONTACT_211533], and the  subject’s  participation in the 
study will end.  
In the event of a subject’s death during the study, the subject’s participation will be 
considered terminated and the date of death will be used as the date of study exit.  
   
Omnipod  
Horizon™ Prepi[INVESTIGATOR_45860] V2. 3 Confidential  Page | [ADDRESS_253432] of the risks  are not unique to the study 
and are typi[INVESTIGATOR_45884], CGM , and BG meters . 
The known risks are as follows:  
• Hypoglycemia and/or hyperglycemia as a result of change in diet , activity,  
diabetes management or  insulin regimen during the study . 
• Hypoglycemia , hyperglycemia , diabetic ketoacidosis , seizure, coma or death 
related to insulin administration, pump use or misuse, or Horizon ™ System 
use or misuse . 
• Use of the Pod (Omnipod® tubeless, insulin delivery  pump) - Because the 
Pod uses only rapid -acting insulin, users are at increased risk for developi[INVESTIGATOR_45885]. If it is untreated, prolonged  
hyperglycemia can quickly lead to diabetic ketoacidosis (DKA) . DKA can 
cause symptoms such as breathing difficulties, shock, coma, or death.  
Further, occlusions can interrupt insulin deliver y and lead to hyperglycemia 
or DKA. Other potential risks associated with using the Pod are:  
o Anaphylaxis  (allergic shock ) 
o Bruising at the Pod site  
o Bleeding at the Pod site  
o Erythema ( redness at the Pod site) 
o Excoriation  (raw skin at Pod site) 
o Pruritus (i tching) 
o Induration  (hardening of the skin at the Pod site) 
o Infection  (can include heat, redness, swelling, pain, and drainage ) 
o Inflammation ( redness, swelling ) 
o Skin reaction to adhesive at the Pod site  
o Papu le (small, solid raised area on the skin similar to a pi[INVESTIGATOR_45886] ) 
o Pain or discomfort  
   
Omnipod  
Horizon™ Prepi[INVESTIGATOR_45860] V2. 3 Confidential  Page | 43 
o Ulceration ( skin sores ) 
o Vesicles (blisters)  
• Use of the CGM - risk of bruising, infection, pain and/or bleeding at the site 
of insertion,  and skin site reaction to adhesive . 
• On rare occasions, the CGM sensor may break  and leave a small portion of 
the sensor under the skin that may cause redness, swelling, or pain at the 
insertion site , and may require surgical removal . 
• Blood sampling with fingerstick - minor discomfort and risk of infection at site 
of fingerstick . 
There are several potential benefits from this study. The Omnipod Horizon™ 
System is designed to provide automated glucose control. The system is expected 
to reduce hypoglycemia without incurring an unacceptable increase  in 
hyperglycemia and mean glucose. The system is also expected to reduce the 
extent and  magnitude of hyperglycemia associated with meals. The Omnipod 
Horizon™ System  uses a control -to-target strategy  that attempts to achieve and 
maintain a set target glucose level.  
11.2 Hypoglycemia/Hyperglycemia  
Subjects will be asked to treat per their usual routine if they suspect either 
hypoglycemia  or hyperglycemia , either by [CONTACT_45947] a 
fingerstick BG, symptoms, or perceived risk .  
Subjects will be encouraged to manage their hyperglycemia per their usual 
routine . This includes checking for ketones using the study -approved ketone 
meter and administering a correction bolus if needed.  
In the event of unexplained hyperglycemia, where  the CGM is >300mg/dL  for 1h 
or >250 mg/dL for 2h , blood glucose (measured with BG meter) and ketones 
should be checked. If BG is ≥300 mg/dL and ketones are >1 .0 mmol/L, an 
occlusion or dislodged cannula should be suspected. The Pod should be 
removed,  and the subject will be i nstructed to replace the Pod. Subjects should 
contact [CONTACT_211534] . This prolonged  hyperglycemic event , defined as  
meter BG  ≥300 mg/dL and ketones >1 .0 mmol/L , will be recorded as a n adverse 
event and cause may be attributed to suspected occlusion if the cannula is in situ 
or dislodged cannula if it has been pulled out. Pods will be requested to be 
returned to Insulet for analysis.  An Adverse Event form will be  completed per the 
Reportable Adverse Events  section below . 
11.3 Adverse Events  
11.3.1  Definitions  
Adverse E vent (AE) : is defined as any untoward medical occurrence , unintended 
disease or injury, or any untoward clinical signs (including an abnormal  laboratory 
finding)  in subject s, users or other persons, whether or not related to the 
investigational medical device.  
   
Omnipod  
Horizon™ Prepi[INVESTIGATOR_45860] V2. 3 Confidential  Page | 44 
NOTE 1: This includes events related to the investigational medical device or the 
comparator.28 
NOTE 2: This definition includes events related to the procedures involved (any 
procedure in the clinical investigation plan).28 
Serious Adverse Event (SAE):  Any untoward medical occurrence that : 
o Led to death  
o Led to serious deterioration in the health of the subject,  that either 
resulted in : 
▪ a life-threatening illness or injury, or  
▪ a permanent impairment of a bo dy structure or a body function, or  
▪ in-patient or prolonged hospi[INVESTIGATOR_059], or  
▪ medical or surgical intervention to prevent life-threatening illness 
or injury or permanent impairment to a body structure or a body 
function.  
o Led to fetal distress, fetal death, or a congenital abnormality or birth defect.  
 
NOTE: Planned hospi[INVESTIGATOR_272] a pre -existing condition, or a 
procedure required by [CONTACT_5745], without serious 
deterioration in health, is not considered a serious adverse event.[ADDRESS_253433] (UADE):  Any serious adverse effect on 
health or safety or an y life-threatening problem or death caused by, or associated 
with, a device, if that effect, problem, or death was not previously identified in 
nature, severity, or degree of incidence in the investigational plan or application 
(including a supplementary p lan or application), or any other unanticipated serious 
problem associated with a device that relates to the rights, safety, or welfare of 
participants . [ADDRESS_253434] (ADE):  An adverse device effect is an adverse event 
related to the use of an investigational medical device . 28  
NOTE 1: This definition includes any adverse event resulting from insufficient or 
inadequate instructions for use, deployment, implantation, installation, or 
operation, or any malfunction of the investigatio nal medical device.28 
NOTE 2: This definition includes any event resulting from use r error or from 
intentional misuse of the investigational medical device.[ADDRESS_253435] (SADE):  A serious adverse device effect is 
defined as an adverse device effect that has resulted in any of the consequences 
characteristic of a serious adverse event. 28 
Device Deficiency  (DD) : A device deficiency is defined as a device related 
complaint or malfunction  or any inadequacy of a device with respect to its identity, 
quality, durability, reliability, safety or performance  and includes misuse or use 
errors and inadequate labeling.  A device deficiency  is something that happens to 
a device or is related to device performance, whereas an adverse event happens 
to a participant. A device deficiency may occur independently from an AE, or 
   
Omnipod  
Horizon™ Prepi[INVESTIGATOR_45860] V2. 3 Confidential  Page | 45 
along with an AE. An AE may occur without a device deficiency or there may be 
an AE related to a device deficiency.   
Note: for reporting purposes, sites will not be asked to distinguish between device 
complaints and malfunctions.   
For any event where there is suspi[INVESTIGATOR_45887], the 
Sponsor  will request that the investigator return the device for evaluation.  
All device complaints  or malfunctions involving any investigational component of 
the Omnipod Horizon™  System used in the study will be reported to the Sponsor  
within [ADDRESS_253436] associate d with a reported device deficiency 
(PDM, Pod, and CGM) should be retained at the clinical  site and returned to the 
Sponsor  or CGM manufacturer for investigation and analysis.  
11.3.[ADDRESS_253437] therapy phase 
(i.e., insertion of the CGM sensor) and continue through the hybrid closed -loop 
phase until the subject’s  participation has ended . All adverse ev ents must be 
followed until resolution, or until the AE has stabilized, or until the study has been 
completed.  
Pre-existing medical conditions or symptoms observed  prior to the start time  of the 
standard therapy phase will not be recorded as an AE  and shou ld be collected in 
the subject’s medical history . In the event there is a change  (i.e., worsening)  in the 
pre-existing medical condition or symptoms after enrollment meeting the criteria of 
a reportable adverse event , then an AE must be re ported. 
For this protocol, a reportable adverse event includes any untoward medical 
occurrence that meets one of the following criteria:  
1. An SAE  
2. An ADE unless excluded from reporting in Hypoglycemic Events  and 
Hyperglycemic/Ketotic Events  section s below  
3. An AE occurring in association with a study procedure  
4. An AE not related to a study  device issue which leads to temporary or 
permanent discontinuation of the study device  
5. An AE that affects the participant’s ability to complete any study 
procedures  
6. An AE for whic h a visit is made to a hospi[INVESTIGATOR_3409]   
7. Hypoglycemi c Events as defined below  
8. Hyperglycemic/Ketotic E vents  as defined below.   
Skin reactions from sensor or pod placement are only reportable if severe and/or 
required treatment.  
   
Omnipod  
Horizon™ Prepi[INVESTIGATOR_45860] V2. 3 Confidential  Page | 46 
For the purpose  of this protocol, mild symptoms of hypoglycemia and 
hyperglycemia (i.e., clinically non -significant)  or blood glucose values out of the 
normal range (whether or not they resulted in delayed meals or correction 
boluses ) will not be reported as AEs unless determined to meet the reportable 
criteria  in the Hypoglycemic Events and Hyperglycemic/Ketotic Events sections  
below . 
All reportable AEs —whether volunteered by [CONTACT_2299], discovered by [CONTACT_211535], or detected through physical examination, 
laboratory test, or other means —will be reported on an AE  eCRF .  
11.3.3  Hypoglycemic Events  
Hypoglycemia is only reportable as an adverse event when  one of  the following  
criteria  is met:   
• Severe Hypoglycemia: The  event required assistance of another person 
due to altered consciousness, and required another person to actively 
administer carbohydrate, glucagon, or other resuscitative actions.25 This 
means that the participant was i mpaired cognitively to the point that he/she 
was unable to treat himself/hersel f, was unable to verbalize his/ her needs, 
was incoherent, disoriented, and/or combative, or experienced se izure or 
loss of consciousness. These epi[INVESTIGATOR_45888]. If plasma 
glucose measurements are not available during such an event, 
neurological recovery attributable to the re storation of plasma glucose to 
normal is considered sufficient eviden ce that the event was induced by a 
low plasma glucose concentration.   
• Hypoglycemia  resulting in an SAE that may not otherwise meet the 
definition of Severe Hypoglycemia defined above.   
 
When a hypoglycemic event meets the above reporting requirements, an Adverse 
Event Form should be completed . A severe hypoglycemia event should be 
consi dered a serious adverse event  and follow the SAE  reporting requirements.  
 
11.3.4  Hyperglycemic/Ketotic Events  
Hyperglycemia is only reportable as an adverse event when any  one of the 
following criteria is met:   
• The event involved DKA, as defined by [CONTACT_45950] (DCCT)24 and described below  
• Evaluation or treatment was obtained at a health care provider facility for 
an acute event involving hyperglycemia or ketosis, or the participant 
contact[CONTACT_45951]/ketosis  
• Prolonged hyperglycemia: defined as meter BG ≥300 mg/dL and ketones 
>1.0 mmol/L  
• Hyperglycemi a resulting in an SAE that may not otherwise meet the above 
criteria  
 
Hyperglycemic events are classified as DKA24 if all of the following are present:  
   
Omnipod  
Horizon™ Prepi[INVESTIGATOR_45860] V2. 3 Confidential  Page | 47 
• Symptoms such as polyuria, polydipsia, nausea, or vomiting;  
• Serum ketones >1.5 mmol/L or large/moderate urine ketones;  
• Either arterial blood pH <7.30 or venous pH <7.24 or serum bicarbonate 
<15; and  
• Treatment provided in a health care facility  
 
When a hyp erglycemia/ketotic event meets the above reporting requirements, 
Adverse Event Form should be completed.  
 
Events meeting DKA criteria should be considered a serious adverse event  and 
follow the SAE  reporting requirements. Hyperglycemia events not meeting criteria 
for DKA generally will not be considered as serious adverse events unless one of 
the SAE criteria above is met.  
 
11.3.5  Relationship of Adverse Event to Investigational Device  
The investigator will be responsible for making a determination on the causal  
relationship of the AE. Specifically, the investigator will report whether the AE was 
related to study procedures and/or related to the investigational device . 
To ensure consistency of adverse event causality assessments, investigators 
should apply the fol lowing general guideline when determining whether an 
adverse event is related:  
The causal relationship to the study procedures and the investigational device for 
each adverse event will  be rated as follows:  
• Unrelated : The event is not related to  the procedures or  the investigational 
device .  
• Possibly Related : The temporal sequence is such that the relationship is 
not unlikely or there is no contradicting evidence that can reasonably 
explain the subject ’s condition. There is a possibility of any relati on 
between the event and the procedures or  the investigational device .  
• Related : The temporal sequence is relevant or the event abates upon 
completion of the procedure/  investigational device, or the event cannot be 
reasonably explained by [CONTACT_423]’s co ndition or comorbidities. The 
event is related or most likely associated with the procedures or the 
investigational device.  
 
11.3.6  Severity (Intensity) of Adverse Events  
The severity (intensity) of an adverse event will be rated on a three -point  scale: (1) 
mild, (2) moderate, or (3) severe. A severity assessment is a clinical determination 
of the intensity of an event. Thus, a severe adverse event is not necessarily 
serious. For example, itching for several days may be rated as severe, but may 
not be clinically serious.  
• MILD: Usually transient, requires no special treatment, and does not 
interfere with the participant’s daily activities.  
   
Omnipod  
Horizon™ Prepi[INVESTIGATOR_45860] V2. 3 Confidential  Page | 48 
• MODERATE: Usually causes a low level of inconvenience, discomfort or 
concern to the participant and may interfe re with daily activities but  is 
usually ameliorated by [CONTACT_45952].  
• SEVERE: Interrupts a participant’s usual daily activities, causes severe 
discomfort, may cause discontinuation of study device,  and generally 
requires systemic drug therapy or other treatment.  
 
11.3.7   Outcome of Adverse Events  
The outcome of each reportable adverse event will be classified by [CONTACT_45953]:  
• RECOVERED/RESOLVED - The participant recovered from the AE/SAE 
without sequelae. Record the AE/SAE stop date.  
• RECOVERED/RESOLVED WITH SEQUELAE - The event persisted and 
had stabilized without further anticipated change in the event status . 
Record the AE/SAE stop date.  
• FATAL - A fatal outcome is defined as the SAE that re sulted in death. Only 
the event that was the cause of death should be reported as fatal.  
AEs/SAEs that were ongoing at the time of death; however, were not the 
cause of death, will be recorded as “resolved” at the time of death.  
• NOT RECOVERED/NOT RESOLVED  (ONGOING) - An ongoing AE/SAE 
is defined as the event was ongoing with an undetermined outcome.  
• An ongoing outcome will require follow -up by [CONTACT_45954]/SAE  or until participant 
completes the study . 
• The outcome of an ongoing event at the time of death that was not the 
cause of death, will be updated and recorded as “resolved” with the 
date of death recorded as the stop date.  
• UNKNOWN - An unknown outcome is de fined as an inability to access the 
participant or the participant’s records to determine the outcome (for 
example, a participant that was lost to follow -up). 
 
If any UADEs are ongoing when a participant completes the study (or withdraws), 
the subject will  continue to be followed until the event  resolve s or has no prospect 
of improvement or change, even after the participant has completed all applicable 
study visits/contacts , unless that subject has withdrawn their consent . For all  other  
reportable adverse events, data collection will end at the time the participant 
completes the study. Note: Participants should continue to receive appropriate 
medical care for an adverse event after their participation in the study ends.  
 
11.4 Reportable Device Issues  
Device com plaints and malfunctions will be reported except in the following 
circumstances. These occurrences are expected and will not be reported on a 
Device Deficiency Form:  
• CGM sensor or Pod lasting fewer days than expected per manufacturer  
• CGM tape or Pod adhere nce issues  
   
Omnipod  
Horizon™ Prepi[INVESTIGATOR_45860] V2. 3 Confidential  Page | 49 
• Battery lifespan deficiency due to inadequate charging or extensive wireless 
communication  
• Intermittent device component disconnections/communication failures not 
requiring system replacement or workaround/resolution not specified in user 
guide/ manual.  
• Device issues clearly addressed in the user guide manual that do not require 
additional troubleshooting  
 
11.[ADDRESS_253438] be reported to the Sponsor/CRO within 2  business days  of the site 
becoming aware of the event. This can occur via phone or email, or by [CONTACT_45955] . If the form is not initially completed, it should be comp leted as 
soon as possible after there is sufficient information to evaluate the event. All 
other reportable AEs should be submitted by [CONTACT_211536] 5 
business days of the site becoming aware of the event .  
Each principal investigator [INVESTIGATOR_211517]/her 
Institutional Review Board or Ethics Committee.  
Upon receipt of a UADE report, the Sponsor will investigate the UADE and if 
indicated, report the results of the investigation to all participating investigators, 
overseeing IRBs, and the FDA within 10 business  days of the Sponsor becoming 
aware of the UADE per 21CFR 812.46(b). Copi[INVESTIGATOR_211518], regulatory authorities, and Sponsor mus t 
be retained with study records.  
The Medical Monitor must notify the DSMB of any UADEs and determine if the 
UADE presents an unreasonable risk to participants. If so, the Sponsor  must 
ensure that all investigations, or parts of investigations presenting that risk, are 
terminated as soon as possible but no later than [ADDRESS_253439] 
receipt notice of the UADE.  
Device deficiencies  will be handled by [CONTACT_45957]. In the case of a Dexcom CGM transmitter or sensor device malfunction, 
information should  be forwarded to Dexcom by [CONTACT_14523], to be handled 
by [CONTACT_45958]’s  complaint management system.  
If the subject is hospi[INVESTIGATOR_45891], then a 
copy of the hospi[INVESTIGATOR_211519]. In case of death, the investigator must make every effort to 
obtain a copy of the death certificate to submit to the Sponsor. When submitting 
copi[INVESTIGATOR_45893], all subject identifying information must be redacted and 
only the unique subject number will be used to label the forms for identification 
purposes.  
For any event where there is suspi[INVESTIGATOR_45887], the 
investigator will return the device for evaluation  when possible . 
 
   
Omnipod  
Horizon™ Prepi[INVESTIGATOR_45860] V2. 3 Confidential  Page | [ADDRESS_253440] (DSMB) will be informed of all cases of 
severe hypoglycemia and diabetic k etoacidosis irrespective of device relationship  
and all UADEs during the study and will review compi[INVESTIGATOR_45894]. The DSMB also will be informed of any SADEs and ADEs not meeting 
criteria for a UADE if the Medical Monitor requests the DSMB review. The DSMB 
can request modifications to the study protocol or suspension or outright stoppage 
of the study if deemed necessary based on the totality of safety data available. 
Details regarding DSMB review will be documented in a separate DSM B Charter . 
 
11.7 Stoppi[INVESTIGATOR_2121]  
11.7.1  Participant Discontinuation of Study Participation  
In the case of a  UADE , use of the study device will be suspended while the 
problem is diagnosed. After assessment of the problem and any correction, use of 
the study device wi ll not be restarted until approval is received from the IRB, 
DSMB, and FDA.  
Use of the study device by a participant will be discontinued if any of the following 
occur:  
• The investigator believes it is unsafe for the participant to continue on the 
interven tion. This could be due to the development of a new medical 
condition or worsening of an existing condition; or participant behavior 
contrary to the indications for use of the device that imposes on the 
participant’s safety . 
• The participant requests that the treatment be stopped  
• Participant pregnancy  
• Two distinct epi[INVESTIGATOR_211520]  
• Two distinct severe hypoglycemia events as defined above  
• One epi[INVESTIGATOR_45896] a single DKA 
or severe hypoglycemia event will be that (1) the site investigator believes that 
the event is explainabl e, unlikely to recur, and that it is safe for the participant to 
continue to use the system and (2) the Medical Monitor concur s. If the Medical 
Monitor determines that the occurrence of the event indicates that it is not safe 
for the participant to continu e to use the system, use will be discontinued,  and the 
subject will be withdrawn from the study . 
 
11.7.2  Criteria for Suspending or Stoppi[INVESTIGATOR_211521], 
who will assess the specif ic event rates for DKA and severe hypoglycemia from 
   
Omnipod  
Horizon™ Prepi[INVESTIGATOR_45860] V2. 3 Confidential  Page | 51 
the study at specific timepoints relative to published rates from large, population -
based datasets.   
 
In consideration of adverse events rates occurring in this proposed the rates will 
be assessed relati ve to published rates from Foster et. al.10 and Miller et. al.26 to 
determine whether severe hypoglycemia or diabetic ketoacidosis are within 
expected rates during this study. Table 6:  T1D Exchange Rates of Severe 
Hypoglycemia and Diabetic Ketoacidosis10,26provides a summary of these 
published rates.  
Table 6:  T1D Exchange Rates of Severe Hypoglycemia and Diabetic 
Ketoacidosis10,26 
Adverse Event  Frequency of subjects to experience ≥ 1 
event extrapolated from T1DX registry 
2016 -2018, 2013 -2014  
Severe hypoglycemia (loss of consciousness or 
seizure)  4-5% < 18 years  
7% ≥ 18 years  
Diabetic ketoacidosis (overnight hospi[INVESTIGATOR_059])  3-4% < 18 years   
2-3% ≥ 18 years  
 
For unanticipated adverse device effects (UADEs), the DSMB  will determine 
whether the study should proceed or not based upon risk of additional serious 
adverse events and the underlying root cause analysis of the UADE.   
 
Study activities could be similarly suspended if the manufacturer of any 
component of the inv estigational  study device requires stoppage of device use for 
safety reasons (e.g. product recall).   
 
The affected study activities may resume if the underlying problem can be 
corrected by a protocol or system modification that will not invalidate the resu lts 
obtained prior to suspension.  
 
The study Medical Monitor will review all adverse events that are reported during 
the study, and the DSMB  will review all cases of severe hypoglycemia, DKA and 
UADEs as well as compi[INVESTIGATOR_27985].  The Medical Monitor 
and/or DSMB may recommend suspension of study activities or stoppage of the 
study to the Sponsor if deemed necessary based on the totality of safety data 
available.  
11.[ADDRESS_253441] (DSMB)  
The DSMB will be established prior  to the  first enrollment and consist, at a 
minimum, of two physicians and one statistician independent from the Sponsor 
and study. The physicians will have relevant therapeutic and medical expert[INVESTIGATOR_18700]. 
The DSMB will determine the s toppi[INVESTIGATOR_211522]. Compi[INVESTIGATOR_211523], device deficiencies, subject terminations, 
and subject withdrawals. In addition, the DSMB members will be notified upon the 
occurrence of any UADEs to  determine whether the study should proceed or not 
   
Omnipod  
Horizon™ Prepi[INVESTIGATOR_45860] V2. 3 Confidential  Page | [ADDRESS_253442] of the DSMB, Sponsor or Medical 
Monitor. At the conclusion of each meeting, the DSMB will make a 
recommendation to the Sponsor concerning the continuation, modification, and/or 
termination, of the study  and/or a statement regarding their overall assessment of 
device safety  and continuation of the pi[INVESTIGATOR_2397] . The final decision regarding 
the continua tion, modification or termination of the study will reside with the 
Sponsor. Responsibilities, qualifications, membership and committee procedures, 
including the final stoppi[INVESTIGATOR_004], will be outlined in the DSMB Charter.  
 
11.[ADDRESS_253443] with the clinical study . 
 
Specific responsibilities of the Medical Monitor include:  
 
• Review of all adverse events reported during the study  
• Review all serious study procedure -related and/or investigational device -
related adverse events to determine if the adverse event warrants 
consideration as a UADE and facilitate the reporting of UADEs if applicable  
• Adjudicate the following(a) all SAEs; (b ) any events of Diabetic Ketoacidosis 
or Severe Hypoglycemia; (c) all AEs reported by [CONTACT_45960]; and/or (d) any additional 
events as requested by [CONTACT_211537].  
• The specified events will be  adjudicated to determine:  
o event relatedness to the study procedures and/or the 
investigational device  
o event categorization and assess seriousness and severity  
o whether an adverse event is anticipated or unanticipated  
The adjudication decision of the Medica l Monitor will be used for the final 
classification of events, including relatedness to the study procedures and/or the 
investigational device, for the determination of safety endpoints and for all 
regulatory reports, product labeling, and publications or presentations.  
 
The Medical Monitor’s roles and responsibilities are described in the Safety 
Management Plan  (SMP) .  
 
 
   
Omnipod  
Horizon™ Prepi[INVESTIGATOR_45860] V2. 3 Confidential  Page | 53 
12 STATISTICAL CONSIDERATIONS  
12.1 Objectives and Endpoints  
12.1.1  Safety Objective  
The safety objective of the study is to evaluate the safety of the Omnipod 
Horizon ™ System in patients with type 1 diabetes . 
[IP_ADDRESS]  Primary Safety Endpoint  
Proportion of subjects with serious device -related adverse events . 
 
[IP_ADDRESS]  Secondary Safety Endpoints  
• Proportion of subjects with severe hypoglycemia during hybrid closed -
loop 
• Proportion of subjects with diabetic ketoacidosis (DKA) during hybrid 
closed -loop 
 
12.1.2  Primary Effectiveness Objective  
The primary effectiveness objective of this study is to evaluate the effectiveness  of 
the Omnipod Horizon ™ System  
 
[IP_ADDRESS]  Primary Effect iveness Endpoints  
The primary effectiveness objective will be evaluated by [CONTACT_211538] (70-180 mg/dL ) during  hybrid closed -loop compared 
to the standard therapy for: 
 
• Target BG challenge days (approximately hybrid closed -loop days 1 -9) 
• Non-challenge days (approximately hybrid closed -loop days 10-14) 
• Overall (hybrid closed -loop days 1 -14) 
 
12.1.3  Secondary Effectiveness Objective  
The secondary objective of the study is to evaluate additional glycemic measures 
of effectiveness  of the Omnipod Horizon ™ System.  
12.1.[ADDRESS_253444] 
endpoints:  
 
• Glucose metrics from system CGM during the hybrid closed -loop phase will 
be compared to th e standard therapy phase during the day, overnight, and 
overall :  
 
• Mean glucose  
   
Omnipod  
Horizon™ Prepi[INVESTIGATOR_45860] V2. 3 Confidential  Page | 54 
• % of time in range 70 -180 mg/dL  
• % of time in range 70 -140 mg/dL  
• % of time > 180 mg/dL  
• % of time ≥ 250 mg/dL  
• % of time ≥ 300 mg/dL  
• % of time < 70 mg/dL  
• % of time < 54 mg/dL  
• Standard deviation  
• Coefficient of variation  
 
• GMI based on overall mean glucose  
• Percentage of time in hybrid closed -loop as proportion of overall device 
usage time  
• Insulin requirements during the hybrid closed -loop phase will be compared to 
the standard therapy phase:  
 
• Total daily insulin (TDI) (units, units/kg)  
• Total daily basal insulin (units, units/kg)  
• Total daily bolus insulin (units, units/kg)  
 
12.2 Sample Size  
This is a single -arm, multi -center, prospective  study . The sample size is not 
hypothesis -driven  and was chosen to provide adequate information on the 
device’s safety and performance.  
12.3 Analysis Sets  
The following analysis sets are planned for the study:  
12.3.1  ITT (Intention to Treat)  Analysis Set  
The ITT analysis set includes all subjects that are enrolled in the study. All safety 
analyses (other than primary analysis of primary safety endpoints) will be based 
on the ITT analysis set.  
12.3.2  mITT ( modified Intention to Treat)  Analysis Set  
The modified Intention to Treat (mITT) analysis set is a subset of the ITT an alysis 
set. The mITT analysis set  will consist of subjects  who have entered the hybrid 
closed -loop phase of the study  successfully.  The mITT analysis set  will be used as 
the primary analysis for the primary and secondary endpoints an d other clinical 
outcom e data.  
12.3.3  PP (Per -Protocol)  Analysis Set  
The Per -Protocol (PP)  analysis set  is a subset of the mITT analysis set. Subjects  
will be included in the PP analysis set  if they have a minimum of  80% system use  
during the hybrid closed -loop phase  inclusive of Manual and Automated Mode s 
over a duration of 14-days and have completed the study without major protocol 
   
Omnipod  
Horizon™ Prepi[INVESTIGATOR_45860] V2. 3 Confidential  Page | 55 
deviations.  The PP analysis set  will be used as supportive analysis for the 
effectiveness endpoints . The following will be considered major protocol 
deviations:  
• Major inclusion/exclusion criterion deviation  
• Significant protocol non -compliance that may confound the study objective 
data (e.g., use of prohibited medications ) 
The list of subjects excluded from the PP analysis set will be determined prior to 
analysis. If the PP analysis set does not differ from the mITT analysis set, 
separate analyses will not be presented.  
12.[ADDRESS_253445] (e.g., day vs. night, overall). The effectiveness  endpoints will 
be summarized for modified Intention to Tre at (mITT) and Per Protocol (PP) 
analysis sets. If the PP analysis set does not differ from the mITT analysis set, 
separate analyses will not be presented. The data may be stratified by [CONTACT_211539], where the data collected in the standard therapy ph ase of the study 
(after adjustment of parameters, if necessary) will be compared to the data 
collected in the hybrid closed -loop phase of the study. The primary effectiveness 
endpoint will also by [CONTACT_211540] G6 use  at the time of 
screenin g (users and non -users).  
The primary effectiveness endpoint and the secondary effectiveness endpoint s 
that summarize time in specific glycemic range s will be calculated  from device 
data outputs  as follows:  
100 ×# 𝑜𝑓 𝐶𝐺𝑀  𝑟𝑒𝑐𝑜𝑟𝑑𝑠  𝑖𝑛 𝑟𝑎𝑛𝑔𝑒  
# 𝑜𝑓 𝑒𝑣𝑎𝑙𝑢𝑎𝑏𝑙𝑒  𝐶𝐺𝑀  𝑟𝑒𝑐𝑜𝑟𝑑𝑠=𝑇𝐼𝑅% 
All statistical comparisons will be conducted at a two -side signifi cance level of 5%. 
Since the results of endpoint analyses are not used to support clinical claims, no 
adjustment for multiplicity will be included. Data from all sites will be pooled for all 
analyses; no separate analyses by [CONTACT_211541].  
12.[ADDRESS_253446] safety and measures may be 
taken to address the issue such as, but not limited to, changes to the protocol 
and/or device. Any resulting device deficiencies  will be reported, if applicable. A 
   
Omnipod  
Horizon™ Prepi[INVESTIGATOR_45860] V2. 3 Confidential  Page | 56 
brief summary of the controller data reviews will be included in the final clinical 
study report.  
 
12.6 Safety Analyses  
12.6.1  Evaluation of Adverse Events  
All adverse events reported over the course of the study will be summarized  and 
tabulated by  [CONTACT_45968] ( standard therapy  or hybrid closed -loop), event 
category, seriousness, severity , and relationship to the study and the 
investigational device. For the purposes of summarization, an event will be 
considered “ Related” if the rel ationship was deemed as “Possibly Related” or 
“Related”. In cases where the same event is reported more than once per subject, 
the event will only be counted once in the incidence table(s).   
Adverse events leading to death or to discontinuation from the study will be listed 
separately.  A listing of all adverse events will be provided.  The primary safety 
endpoint will also be presented by [CONTACT_211542] G6 use  at the time of 
screening  (users and non -users).  
12.6.[ADDRESS_253447] (such as age, gender, medical history, etc.) will be presented. Data on all 
enrolled subjects will be presented. Continuous variables will be summarized 
using count, mean, median, standard deviation, and range. Categorical variables 
will be summarized using counts and percentages.  
12.[ADDRESS_253448]  data 
listings. Unless otherwise noted, all p -values will be considered significant at a 
two-sided significance level of 5%. Continuous variables will be summarized  using 
descript ive statistics, including count , mean, median, standard deviation (SD), 
minimum and maximum. Where appropriate, 95% two -sided confidence intervals 
for the means or medians will be presented. If the observed data are found not to 
follow a nor mal distribution, appropriate non -parametric methods may be 
employed. Categorical variables will be summarized by [CONTACT_45970]. Unless explicitly stated otherwise, percentages will utilize a 
denominator corresponding to the number of unique subjects . 
   
Omnipod  
Horizon™ Prepi[INVESTIGATOR_45860] V2. 3 Confidential  Page | 57 
12.9 Missing D ata 
All practical monitoring and follow -up steps will be taken to ensure complete and 
accurate data collection. It is anticipated that the rate of missing data would be 
very low  due to the limited  duration  of the study . All analys es will be based on 
available data only; no imputation for missing data is planned . 
12.10  Statistical Software  
The statistical software package SAS® 9. 4 or later will be used for all the data 
derivations, summarization, data listings and statistical analyses. Additional 
software such as Splu s or R may be used for graphics or validation as 
appropriate.  
13 DATA HANDLING  AND QUALITY ASSURANCE  
Data in this study will be collected on Electronic Case Report Forms as well as via 
electronic device outputs . 
 
13.1 Electronic Case Report Forms  (eCRFs)  
Study data are collected through a combination of subject electronic CRFs 
(eCRFs)  and electronic device data files. eCRF Data  will be recorded in a  [ADDRESS_253449] be reviewed  and signed  
by [CONTACT_941] i nvestigator in the EDC system . The investigator also agrees to maintain 
accurate source documentation supporting the data . When pertinent supportive 
information is available  for data entered directly into the eCRFs, this supporting 
docu mentation will also be maintained.  S ource documents may include chart 
notes, laboratory reports, images , study specific source worksheets, eCRFs, 
device data files, etc. 
13.2 Electronic Device Outputs  
13.2.1  PDM Data  
This study will utilize insulin delivery data from the PDM device . All insulin delivery 
data and all CGM readings from the hybrid closed -loop phase will be stored on the 
PDM and exported to Insulet Cloud . Data will be saved in a compatible format that 
will be extractable for statistical analysis purpo ses. D ata from the hybrid closed -
loop phase will be uploaded to the database and used for analysis.  
   
Omnipod  
Horizon™ Prepi[INVESTIGATOR_45860] V2. 3 Confidential  Page | [ADDRESS_253450] ’s name.  
13.[ADDRESS_253451] of monitoring visits as well  as identify any 
relevant study -specific monitoring responsibilities.  
Monitor s for this study will be qualified by [CONTACT_8640], experience and tr aining.  The 
monitor  will report to the Sponsor any non -compliance with the protocol, 
applicable regulations , or any conditions  imposed by [CONTACT_32629] B or local regulatory 
authority.  If compliance cannot be secured, device shipments to the Investigator 
may be discontinued and the Investigator’s participation in the study  terminated.  
Investigators and clinical site coordinators are expected to make source files and 
other records and rep orts available to the monitors  as required . 
13.[ADDRESS_253452] copi[INVESTIGATOR_45902].  
   
Omnipod  
Horizon™ Prepi[INVESTIGATOR_45860] V2. 3 Confidential  Page | [ADDRESS_253453] remain on file at the investigational site for a minimum 
of two years after the later of either the completion /termination of the study or the 
date of market approval for the indication being studied. They may be discarded 
only upon approval from the Sponsor. The Principal Investigator [INVESTIGATOR_211524] t o the study to 
ensure that they no longer need to be retained. In addition, the Sponsor  must be 
contact[CONTACT_211543] a new investigator or records transfer are made prior to 
investigator departure . 
13.[ADDRESS_253454] be stored according  to the conditions set forth for the device 
on the label  in a controlled, locked area. All device shipment records (packing 
lists, etc.) must be maintained at the clinical site.  
The study monitor will verify accountability of the study devices during rout ine 
monitoring visits to the clinical site.  
[ADDRESS_253455] 
Research Organization ( CRO ). 
14.[ADDRESS_253456] of the Study  
The investigat ion will be conducted according to the applicable FDA regulations 
(21CFR  812, 56, 54, 50 ). The investigator will conduct all aspects of this study in 
accordance  with all state, and local laws or regulations.  
14.[ADDRESS_253457]  (IRB)  
Federal regulations  (21 CFR 812) require that approval be obtained from an IRB 
prior to participation of subject s in research studies. Prior to subject  enrollment, a 
signed copy of the IRB approval letter must be submitted to the Sponsor.  In 
addition , the protocol, informed consent, adver tisements to be used for subject  
recruitment, and any other written information regarding this study to be provided 
to the subject  must be approved by [CONTACT_1201].  Documentation of all IRB approvals 
   
Omnipod  
Horizon™ Prepi[INVESTIGATOR_45860] V2. 3 Confidential  Page | [ADDRESS_253458] 
identify the IRB by [CONTACT_45972], the clinical protocol by [CONTACT_29985]/or protocol 
number, and the date approval was granted.  
The Investigator is responsible for submitting and obtaining initial and continuing  
review of the trial at intervals not exceeding [ADDRESS_253459] . An informed consent  form (ICF) 
template will be provided by [CONTACT_211544]. 
If any institution -specific modifications to study -related procedures are proposed 
or made by [CONTACT_977], the consent must  be reviewed by [CONTACT_211545]. Once reviewed, the consent will be submitted by [CONTACT_45976].  
Before recruitment and en rollment, each prospective subject  will be given a full 
explanation of the study and be allowed to read the approved ICF. Once the 
investigator  or designee  is assured that the subject  understands the implications 
of participating in the study, the subject  will be asked to give consent to participate 
in the study by [CONTACT_12568]. 
The investigator or designee shall provide a copy of the signed ICF to the subject . 
The original form shall be maintained in the subject  binder  at the clinical site. 
14.[ADDRESS_253460] -protected computers .  
This includes , but is not limited to the following:  
• Subject s will be identified on all eCRFs by a unique subject  ID 
• eCRFs are confidential documents and will only be ava ilable to the Sponsor 
(including delegates, such as CRAs), DSMB, Medical Monitor, CRO, the 
investigator  and study staff , and if requested, to  the IRB or  regulatory 
authorities. The investigator will maintain, as part of the investigation file, a 
list identifying all subject s entered into the study . 
All laboratory specimens, evaluation forms, reports, and other records will be 
identified in a manner designed to maintain subject  confide ntiality. Clinical 
   
Omnipod  
Horizon™ Prepi[INVESTIGATOR_45860] V2. 3 Confidential  Page | [ADDRESS_253461] , 
except as necessary for monitoring and auditing by [CONTACT_1034], its designee, the 
FDA, or the IRB.  
The investigator and all clinical site staff involved in this study may not disclose (or 
use for any purpose other than performance of the study ), any data, record, or 
other unpublished confidential information disclosed to those individuals for the 
purpose of the study. Prior written agreement from the Sponsor o r its designee 
must be obtained for the disclosure of any said confidential information to other 
parties.  
14.[ADDRESS_253462]  be reviewed and approved by [CONTACT_429].  The protocol amendment(s) must be signed by [CONTACT_45977]. The protocol amendment (s) will be 
filed with the appropriate regulatory agency(s) having jurisdiction over  the conduct 
of the study.  
Substantial changes will require approval from the Sponsor, FDA, and IRB prior to 
implementation.  
14.[ADDRESS_253463] ’s risk 
or affect the validity of the trial. In medical emergencies, prior approval for protocol 
deviations will not be required, but the Sponsor  must be notified within [ADDRESS_253464] ’s source documentation. The IRB should be notified of all protocol 
deviations in a timely manner. Protocol deviations should be reported to the IRB 
periodically, according to their requirements. Deviations will a lso be reviewed  by 
[CONTACT_45978].  
The Sponsor will evaluate circumstances where the investigator deviates from the 
study  protocol and will retain the right to remove either the investigator or the 
inves tigational clinical site from the study.  
   
Omnipod  
Horizon™ Prepi[INVESTIGATOR_45860] V2. 3 Confidential  Page | 62 
14.8 Study Reporting Requirements  
By [CONTACT_4907], the investigator agrees to submit SAE reports 
according to the timeline and method outlined in  this protocol.  In addition, the 
investigator agrees to submit a nnual reports to his/her IRB  as appropriate.  
Upon completion or termination of the study , the principal investigator (PI) must 
submit a final written report to the Sponso r and IR B. The report must be submitted 
within 3 months (90 days) of completion or termination of the trial.  
The Sponsor will submit all reports required by [CONTACT_45979], including unanticipated adverse device effects, withdrawal of IRB 
approval, list of current investigators , annual progress reports, recall information, 
final r eports and pro tocol deviations . 
14.[ADDRESS_253465] qualified investigators, ship devices only to participating 
investigators, obtain a signed Investigator’s Agreement and provide all 
investigators with the information and training necessa ry to conduct the study.  
14.9.[ADDRESS_253466] notify the Sponsor promptly o f any relevant changes that occur during the 
course of the study , at the completion of the study , and 1 year following the 
completion of the study.  
14.9.2  Investigator Documentation  
Prior to beginning the study, the investigator will be asked to comply with 21 CFR 
812 by [CONTACT_44074], including but not limited to:  
• An investigat or-signed Investigator Agreement page of the protocol  
• An IRB approved informed consent, samples of clinical site advertisements 
for recruitment for this study, and any other written information regarding this 
study that is to be provided to the subject  
• IRB approval of the investigator, protocol, and acknowledgement of the user 
guide  
• Curricula vitae (CV) for the PI [INVESTIGATOR_45904] . Current licensure must be noted on the CV or a copy of the license 
provided . CVs must be sig ned and dated by [CONTACT_45980] 1 year of 
study start -up, indicating that they are accurate and current.  
• Financial disclosure information  (as stated above) and a commitment to 
promptly update this information if any relevant changes occur  
   
Omnipod  
Horizon™ Prepi[INVESTIGATOR_45860] V2. 3 Confidential  Page | 63 
• Laborat ory certifications and normal ranges for any local laboratories used 
by [CONTACT_977]. 
14.[ADDRESS_253467]  care.  
14.11  Device Use 
The Omnipod Horizon ™ System  consist s of the following primary components : 
an Omnipod  Horizon™ Pod, Omnipod Horizon™ Controller , and the iCGM . 
The Pod and PDM are  intended for single use only.  
The Dexcom G6 CGM sensor (the component of the system that enters the 
skin) and the Dexcom G6 CGM t ransmitter (the component of the system that 
attaches to the sensor to transmit the signal) will both be single use only  in this 
study . The Dexcom G6 CGM receiver will all be single use only in this study . 
Study blood glucose meters and ketone meters  will not be cleaned or reused by 
[CONTACT_1766]. A new meter will be used  for each subject.  
14.[ADDRESS_253468] the Sponsor  
representative and provide the following information:  
• Part number/Lot number  
• Quantities  
• Tracking number  
14.13  Policy for P ublicat ion and Presentation of D ata 
All data and results and all intellectual property rights in the data and results 
derived from the study will be the property of the study Sponsor, Insulet .  
   
Omnipod  
Horizon™ Prepi[INVESTIGATOR_45860] V2. 3 Confidential  Page | [ADDRESS_253469]  follow -
up shall be reported on the eCRF .  
   
Omnipod  
Horizon™ Prepi[INVESTIGATOR_45860] V2. 3 Confidential  Page | 65 
REFERENCES  
1. Centers for Disease Control and Prevention. “Diabetes Report Card 2012” Atlanta, GA: 
Centers for Disease Contr ol and Prevention, US Department of Health and Human Services 
(2012).  
2. Nathan, DM et al. “Intensive diabetes treatment and cardiovascular disease in patients with 
type 1 diabetes”. N. Engl. J. Med. 353: 2643 -2653 (2005).  
3. Cryer, PE “Banting lecture. Hypoglyc emia: the limiting factor in the management of IDDM”. 
Diabetes 43: 1378 -1389, (1994).  
4. Weinstock RS et al. “Severe hypoglycemia and diabetic ketoacidosis in adults with type 1 
diabetes: results from the T1D Exchange clinic registry ” J Clin Endocrinol Metab.  
98(8):3411 -3419 (2013).  
5. Livingstone SJ et al. “Estimated life expectancy in a Scottish cohort with type 1 diabetes 
2008 -2010”. JAMA . Jan 6;313(1):37 -44 (2015).  
6. Lind M et al. “Glycemic control and excess mortality in type 1 diabetes”. N Engl J Med. 
20;371( 21):1972 -1978 (2014).  
7. American Diabetes Association “Treatment Guidelines: Children and adolescents”. Diabetes 
Care  2015;38 (Suppl.):S70 -S76 (2015).  
8. Nathan DM et al., “Translating the A1C assay into estimated average glucose values” 
Diabetes 31:1-6 (2008).  
9. Beck RW et al., “The T1D Exchange clinic registry“ J Clin Endocrinol Metab. 97(12):4383 -
4389 (2012).  
10. Foster NC  et al., “ State of Type 1 Diabetes Management and Outcomes from the T1D 
Exchange in 2016 -1018 ” Diabetes Technology Ther . Volume 21(2) pp. 66-72 (2019). 
11. Beck SE, “The content of Investigational Device Exemption and Premarket Approval (PMA) 
applications for Artificial Pancreas Device Systems” UCM259305 (November 9, 2012).  
12. Centers for Disease Control and Prevention – Physical Activity Basics: 
https://www.cdc.gov/physicalactivity/basics/index.htm?CDC_AA_refVal=https%3A%2F%2F
www.cdc.g ov%2Fphysicalactivity%2Fbasics%2Fmeasuring%2Fheartrate.htm  
13. Buckingham B, Pi[INVESTIGATOR_45905], Christiansen M, Schneider J, Peyser T, Dassau E, Lee JB, 
O'Connor J, Layne JE, Ly TT. Feasibility of Omnipod Hybrid Closed -loop Control in Adults 
With Type 1 Diabetes Usin g a Personalized Model Predictive Control Algorithm. Diabetes 
Technol Ther.  2017;19(S1):A18 -A19.  
14. Buckingham B, Forlenza GP, Schneider J, Peyser T, Dassau E, Lee JB, O'Connor J, Layne 
JE, Ly TT. Safety and Feasibility of Omnipod Hybrid Closed -Loop in Childr en Aged 6 -12 
Years with Type 1 Diabetes Using a Personalized Model Predictive Control Algorithm. 
Diabetes . 2017;66(S1A):LB34.  
15. Buckingham B, Forlenza GP, Schneider J, Peyser T, Dassau  E, Lee JB, O'Connor J, Layne 
JE, Ly TT. Safety and Feasibility of Omnipod Hybrid Closed -Loop in Adolescents with Type 
   
Omnipod  
Horizon™ Prepi[INVESTIGATOR_45860] V2. 3 Confidential  Page | 66 
1 Diabetes Using a Personalized Model Predictive Control Algorithm. Diabetes . 
2017;66(S1):A278.  
16. Forlenza GP, Buckingham B, Christiansen M , Wadwa RP, Peyser T, Lee JB, O'Connor J, 
Dassau E, Layne JE, Ly TT. Performance of Omnipod Personalized Model Predictive 
Control Algorithm With Moderate Intensity Exercise and Variable Setpoints in Adults With 
Type 1 Diabetes. Diabetes Technol Ther.  2018; 20(S1):A56 -A57.  
17. Buckingham B, Christiansen M, Forlenza GP, Wadwa RP, Peyser T, Lee JB, O'Connor J, 
Dassau E, Layne JE, Ly TT. Performance of Omnipod Personalized Model Predictive 
Control Algorithm With Specific Meal Challenges in Adults With Type 1 Diabete s. Diabetes 
Technol Ther . 2018;20(S1):A12 -A13. 
18. Buckingham BA, Christiansen MP, Forlenza GP, Wadwa RP, Peyser TA, Lee JB, O'Connor 
J, Dassau E, Huyett LM, Layne JE, Ly TT. Performance of the Omnipod Personalized Model 
Predictive Control Algorithm with Meal Bolus Challenges in Adults with Type 1 Diabetes. 
Diabetes Technol Ther.  2018;20(9):585 -595. 
19. Buckingham BA, Forlenza GP, Pi[INVESTIGATOR_45905], Christiansen MP, Wadwa RP, Schneider J, 
Peyser TA, Dassau  E, Lee JB, O'Connor J, Layne JE, Ly TT. Safety and feasibility of the 
OmniPod hybrid closed -loop system in adult, adolescent, and pediatric patients with type 1 
diabetes using a personalized model predictive control algorithm. Diabetes Technol Ther.  
2018; 20(4):257 -262. 
20. Buckingham B, Sherr J, Forlenza GP, Peyser T, Lee JB, O'Connor J, Dumais B, Huyett LM, 
Layne JE, Ly TT. Safety and Performance of the Omnipod Hybrid Closed -Loop System Over 
5 Days of Outpatient Use in Adults with Type 1 Diabetes. Diabetes . 2018;67(S1):A55.  
21. Forlenza GP, Buckingham B, Sherr J, Peyser T, Lee JB, O'Connor J, Dumais B, Huyett LM, 
Layne JE, Ly TT. Safety and Performance of the Omnipod Hybrid Closed -Loop System in 
Adolescents with Type 1 Diabetes Over 5 Days Under Free -Living Condit ions. Diabetes . 
2018;67(S1):A369.  
22. Sherr J, Forlenza GP, Buckingham B, Peyser T, Lee JB, O'Connor J, Dumais B, Huyett LM, 
Layne JE, Ly TT. Safety and Performance of the Omnipod Hybrid Closed -Loop System in 
Children with Type 1 Diabetes Over 5 Days Under Fre e-Living Conditions. Diabetes . 
2018;67(S1):A369.  
23. Forlenza GP, Buckingham BA, Christiansen MP, et al. Performance of Omnipod 
Personalized Model Predictive Control Algorithm with Moderate Intensity Exercise in Adults 
with Type [ADDRESS_253470] of intensive 
treatment of diabetes on the development and progression of long -term complications in 
insulin -dependent diabetes mellitus. N Engl J Med 1993;329:[ADDRESS_253471] WV, T1D Exchange Clinic Network. Current state of type 1 diabetes treatment 
in the US: updat ed data from the T1D Exchange clinic registry. Diabetes Care. 
2015;38(6):971 -8 
27. U.S. Department of Health and Human Services. Physical Activity Guidelines for Americans, 
2nd edition. Washington, DC: U.S. Department of Health and Human Services; 2018.  
   
Omnipod  
Horizon™ Prepi[INVESTIGATOR_45860] V2. 3 Confidential  Page | 67 
28. ISO [ZIP_CODE]:2011 (E), Clinical investigation of medical devices for human subjects – Good 
clinical practice, second edition 2011 -02-01. 
29. Sherr J, Buckingham BA, Forlenza G, et al. Safety and Performance of the Omnipod Hybrid 
Closed -Loop System in Adults, Adolesce nts, and Children with Type 1 Diabetes Over 5 
Days Under Free -Living Conditions. Diabetes Technol Ther. 2019.  
  
   
Omnipod  
Horizon™ Prepi[INVESTIGATOR_45860] V2. 3 Confidential  Page | 68 
APPENDIX  
 
